



PCT/PTO
10/534584
PCT/GB03/14969
11 MAY 2005



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 23 DEC 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

P. Mahoney

Dated 15 December 2003

BEST AVAILABLE COPY

The
Patent
Office



1/77

Request for grant of a patent
the notes on the back of this form. You can also get
explanatory leaflet from the Patent Office to help
fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Your reference

T1607PV

18NOV02 E764007-1 002639
P01/7700 0.00-0226724.3

Patent application number
(The Patent Office will fill in this part)

0226724.3

15 NOV 2002

Full name, address and postcode of the or of
each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001

If the applicant is a corporate body, give the
country/state of its incorporation

United Kingdom

00597799001

Title of the invention

Therapeutic agents

Name of your agent (if you have one)

Mr. I. J. Hiscock

Address for service" in the United Kingdom
which all correspondence should be sent
including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

06546683001

If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day/month/year)

Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

Yes

any applicant named in part 3 is not an inventor, or
there is an inventor who is not named as an
applicant, or
any named applicant is a corporate body.
See note (d))

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	63
Claim(s)	0
Abstract	0
Drawing(s)	0

CM

If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

1.

I/We request the grant of a patent on the basis of this application.

Signature

Mr. I. J. Hiscock

Date 15 November 2002

2. Name and daytime telephone number of person to contact in the United Kingdom

Mr. I. J. Hiscock

01279 440175

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTS

The present invention is concerned with substituted amino-heterocycles and pharmaceutically acceptable salts and prodrugs thereof which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).


The pharmacologically active ingredient of chilli peppers has been recognised for some time to be the phenolic amide capsaicin. The application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans. The beneficial effects of topical administration of capsaicin as an analgesic is also well established. However, understanding of the underlying molecular pharmacology mediating these responses to capsaicin has been a more recent development.

The receptor for capsaicin, termed the vanilloid VR1 receptor, was cloned by Caterina and colleagues at UCSF in 1997 (*Nature*, 398:816, 1997). VR1 receptors are cation channels that are found on sensory nerves that innervate the skin, viscera, peripheral tissues and spinal cord. Activation of VR1 elicits action potentials in sensory fibres that ultimately generate the sensation of pain. Importantly VR1 receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli. It is also sensitized by a number of inflammatory mediators and thus appears to be a polymodal integrator of painful stimuli.

The prototypical VR1 antagonist is capsazepine (Walpole *et al.*, *J. Med. Chem.*, 37:1942, 1994) – VR1 IC₅₀ of 420nM. A novel series of sub-micromolar antagonists has also been reported recently (Lee *et al.*, *Bioorg. Med. Chem.*, 9:1713, 2001), but these reports provide no evidence for *in vivo* efficacy. A much higher affinity antagonist has been derived from the 'ultra-potent' agonist resiniferatoxin. Iodo-resiniferatoxin (Wahl *et al.*, *Mol. Pharmacol.*, 59:9, 2001) is a nanomolar antagonist of VR1 but does not possess properties suitable for an oral pharmaceutical. This last is also true of the micromolar peptoid antagonists described by Garcia-Martinez (*Proc. Natl. Acad. Sci., USA*, 99:2374, 2002). Most recently International (PCT) patent publication No. WO 02/08221 has described a novel series of VR1 antagonists, which are stated to show efficacy in a number of animal models. We herein

describe another novel series of VR1 modulators. These comprise predominantly VR1 antagonists but encompass VR1 partial antagonists and VR1 partial agonists. Such compounds have been shown to be efficacious in animal models of pain.

5 The present invention provides compounds of formula (I):



(I)

wherein

V represents NR⁵, O, S, SO or S(O)₂;

10 W and X each independently represent CH or N;

Y represents N, CH or C-Ar₂, with the proviso that at least one, but no more than two, of W, X and Y are N;

Z represents CH or C-Ar₂, with the proviso that when Y is N or CH then Z is C-Ar₂, and with the further proviso that when Y is C-Ar₂ then Z is CH;

15 Ar₁ represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic;

Ar₂ represents an aromatic ring selected from phenyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, which aromatic ring is unsubstituted or substituted

20 by one, two or three groups selected from halogen, hydroxy, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, C₃₋₅cycloalkylC₁₋₄alkyl, cyano, nitro, SR⁶, SOR⁶, SO₂R⁶, COR⁶, NR³COR⁶, CONR³R⁴, NR³SO₂R⁶, SO₂NR³R⁴, -(CH₂)_mcarboxy, esterified -(CH₂)_mcarboxy and -(CH₂)_mNR³R⁴;

25 R¹ represents halogen, hydroxy, oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, C₃₋₅cycloalkylC₁₋₄alkyl, cyano, nitro, SR⁶, SOR⁶, SO₂R⁶, COR⁶, NR³COR⁶, CONR³R⁴, NR³SO₂R⁶, SO₂NR³R⁴, -(CH₂)_mcarboxy, esterified -(CH₂)_mcarboxy or -(CH₂)_mNR³R⁴;

R² represents hydrogen, halogen, hydroxy, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy or haloC₁₋₆alkoxy;

5 R³ and R⁴ are each independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl or fluoroC₁₋₆alkyl;

or R³ and R⁴ and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C₁₋₄alkoxy, which ring may optionally contain as
10 one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)₂, or NR⁵;

R⁵ represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

R⁶ represents hydrogen, C₁₋₆alkyl, fluoroC₁₋₆alkyl, C₃₋₇cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy or haloC₁₋₆alkoxy;

15 m is either zero or an integer from 1 to 4;

n is either zero or an integer from 1 to 3;

or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

A preferred class of compound of formula (I) is that wherein R¹ is halogen, especially fluorine, C₁₋₄alkyl, especially methyl, or fluoroC₁₋₄alkyl, especially
20 trifluoromethyl.

Preferably n is zero, one or two, and especially one or two.

A further preferred class of compound of formula (I) is that wherein R² is a hydrogen or a halogen atom, or a group selected from C₁₋₄alkyl, C₁₋₄alkoxy and phenyl substituted by C₁₋₄alkyl or fluoroC₁₋₄alkyl.

25 More particularly, R² preferably represents a hydrogen or chlorine atom or a group selected from methyl, methoxy and *p*-trifluoromethylphenyl. Most preferably, R² is a hydrogen atom or a methyl group.

It will be appreciated that the group R² is attached to any available carbon atom including those represented by W, X, Y and Z.

30 A further preferred class of compound of formula (I) is that wherein R³ is a hydrogen atom or a C₁₋₄alkyl group, particularly a hydrogen atom or a methyl group, and most especially a hydrogen atom.

A yet further preferred class of compound of formula (I) is that wherein R^4 is a hydrogen atom or a C_{1-4} alkyl group, particularly a hydrogen atom or a methyl group, and most especially a hydrogen atom.

When present, R^3 is preferably a hydrogen atom or a C_{1-4} alkyl group, and
5 R^4 is preferably a hydrogen atom or a C_{1-4} alkyl group, or the group NR^3R^4 represents a heteroaliphatic ring selected from azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, piperaziny or a piperaziny group substituted on the nitrogen atom by C_{1-4} alkyl optionally substituted by hydroxy or C_{1-4} alkoxy. More preferably, the group NR^3R^4 represents a group selected from
10 $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCH_2CH_3$, $-N(CH_3)CH_2CH_3$ and $-N(CH_2CH_3)_2$, and most especially, $-N(CH_3)_2$.

When present, R^5 is preferably hydrogen or C_{1-4} alkyl (e.g. methyl), and especially hydrogen.

Another preferred class of compound of formula (I) is that wherein V is
15 NH or O, and especially NH.

A further preferred class of compound of formula (I) is that wherein $=W-X=Y-$ represents $=N-CH=CH-$, $=N-N=CH-$, $=N-CH=N-$ or $=N-N=C(Ar_2)-$.

Particularly preferred are those compounds of formula (I) where W is N.

Also particularly preferred are those compounds of formula (I) where Y is
20 N or CH.


A further preferred class of compound of formula (I) is that wherein Z is $C-Ar_2$.

Another preferred class of compound of formula (I) is that wherein Ar_1 represents a heterobicyclic ring system selected from isoquinoline, indazole,
25 triazolopyridine (especially triazolo[1,5-a]pyridine), cinnoline, benzothiazole, imidazopyridine (especially imidazo[1,5-a]pyridine and imidazo[1,2-a]pyridine), quinolinone, tetrahydroisoquinoline, and dihydroquinolinone. Particularly preferred heterobicyclic ring systems are selected from isoquinoline, indazole, imidazo[1,5-a]pyridine, quinolin-2(1H)-one and 3,4-dihydroquinolin-2(1H)-one.
30 Most preferably, the group Ar_1 is attached to the remainder of the molecule through the carbon atom adjacent to one of the bridgehead atoms.

Yet another preferred class of compound of formula (I) is that wherein Ar_2 represents unsubstituted phenyl or phenyl substituted by one or two substituents selected from halogen, cyano, C_{1-4} alkyl, fluoro C_{1-4} alkyl, C_{1-4} alkoxy and

fluoroC₁₋₄alkoxy. In particular, Ar₂ preferably represents a phenyl ring substituted by one substituent selected from fluorine, cyano, methyl, *tert*-butyl, trifluoromethyl, methoxy and trifluoromethoxy. Aptly, the substituent is attached at the 4-position of the phenyl ring.


- 5 One favoured class of compound of the present invention is that of formula (Ia) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:



- 10 wherein -X'=Y'- represents -CH=CH-, -N=CH- or -CH=N-, and R¹, R², Ar₁, Ar₂ and n are as defined in formula (I).

Another favoured class of compound of the present invention is that of formula (Ib) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:

15




wherein -X'=Y'- represents -CH=CH-, -N=CH- or -CH=N-, -A-B- is selected from the group consisting of:

- | | |
|-------------------|------------------|
| (a) -CH=CH-N=CH-, | (e) -CH=N-CH=N-, |
| (b) -CH=CH-CH=N-, | (f) -N=CH-CH=N-, |
| (c) -CH=CH-N=N-, | (g) -CH=CH-NH-, |
| (d) -CH=N-N=CH-, | (h) -CH=CH-O-, |


- | | | | |
|-----|---|-----|--|
| (i) | $-\text{CH}=\text{CH}-\text{S}-$, | (s) | $-\text{CH}_2-\text{CH}_2-\text{N}=\text{CH}-$, |
| (j) | $-\text{N}=\text{CH}-\text{NH}-$, | (t) | $-\text{CH}_2-\text{CH}_2-\text{NH}-\text{CH}_2-$, |
| (k) | $-\text{CH}=\text{N}-\text{NH}-$ | (u) | $-\text{CH}_2-\text{NH}-\text{C}(\text{O})-\text{NH}-$, |
| (l) | $-\text{O}-\text{CH}=\text{N}-$, | (v) | $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{NH}-$, |
| (m) | $-\text{CH}=\text{N}-\text{O}-$, | (w) | $-\text{CH}_2-\text{NH}-\text{S}(\text{O})-\text{NH}-$, |
| (n) | $-\text{S}-\text{CH}=\text{N}-$, | (x) | $-\text{CH}_2-\text{NH}-\text{SO}_2-\text{NH}-$, |
| (o) | $-\text{CH}=\text{N}-\text{S}-$, | (y) | $-\text{CH}_2-\text{CH}_2-\text{C}(\text{O})-\text{NH}-$, |
| (p) | $-\text{N}=\text{N}-\text{NH}-$, | | and |
| (q) | $-\text{CH}_2-\text{CH}_2-\text{CH}=\text{N}-$, | (z) | $-\text{CH}=\text{CH}-\text{C}(\text{O})-\text{NH}-$; |
| (r) | $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{NH}-$, | | |

and R^1 (which may be on either or both of the rings of the heterobicyclic ring system), R^2 , Ar_2 and n are as defined in formula (I).

Another favoured class of compound of the present invention is that of
 5 formulae (Ic) and (Id) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:



(Ic)



(Id)


10 wherein $-\text{X}'=\text{Y}'-$ represents $-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-$, $-\text{A}-\text{B}-$ is selected from the group consisting of:

- | | |
|-----|--|
| (a) | $=\text{CH}-\text{CH}=\text{N}-$, |
| (b) | $=\text{CH}-\text{N}=\text{CH}-$, |
| (c) | $=\text{N}-\text{CH}=\text{CH}-$, and |
| (d) | $=\text{CH}-\text{CH}=\text{CH}-$; |

15

and R^1 (which may be on either or both of the rings of the heterobicyclic ring system), R^2 , Ar_2 and n are as defined in formula (I).

A further favoured class of compound of the present invention is that of formulae (Ie) and pharmaceutically acceptable salts, N-oxides and prodrugs thereof:



wherein $-X'=Y'$ represents $-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-$, $-A-B-$ is selected from the group consisting of:

- (a) $-\text{CH}=\text{CH}-\text{CH}=\text{N}-$,
- (b) $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$,
- (c) $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$,
- (d) $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$,
- (e) $-\text{CH}=\text{CH}-\text{NH}-$,
- (f) $-\text{CH}=\text{N}-\text{NH}-$,
- (g) $-\text{N}=\text{CH}-\text{NH}-$, and
- (h) $-\text{CH}=\text{CH}-\text{O}-$;

and R^1 (which may be on either or both of the rings of the heterobicyclic ring system), R^2 , Ar_2 and n are as defined in formula (I).

When any variable occurs more than one time in any of formulae (I), (Ia), (Ib), (Ic), (Id) and (Ie) or in any substituent, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples

of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.

As used herein, the term "hydroxyC₁₋₆alkyl" means a C₁₋₆alkyl group in which one or more (in particular 1 to 3, and especially 1) hydrogen atoms have been replaced by hydroxy groups. Particularly preferred are hydroxyC₁₋₃alkyl groups, for example, CH₂OH, CH₂CH₂OH, CH(CH₃)OH or C(CH₃)₂OH, and most especially CH₂OH.

As used herein, the terms "haloC₁₋₆alkyl" and "haloC₁₋₆alkoxy" means a C₁₋₆alkyl or C₁₋₆alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. Preferred are fluoroC₁₋₆alkyl and fluoroC₁₋₆alkoxy groups, in particular, fluoroC₁₋₃alkyl and fluoroC₁₋₃alkoxy groups, for example, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, OCF₃, OCH₂CH₂F, OCH₂CHF₂ or OCH₂CF₃, and most especially CF₃, OCF₃ and OCH₂CF₃.

The cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Suitable C₃₋₇cycloalkylC₁₋₄alkyl groups include, for example, cyclopropylmethyl and cyclohexylmethyl.

Similarly cycloalkoxy groups referred to herein may represent, for example, cyclopropoxy or cyclobutoxy.

As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is acetylene or propargyl.

When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine. The most apt halogens are fluorine and chlorine of which fluorine is preferred, unless otherwise stated.

When used herein, the term "carboxy" as a group or part of a group denotes CO₂H.

When used herein, the term "esterified carboxy" denotes a C₁₋₆alkoxy or a haloC₁₋₆alkoxy radical attached via the oxygen atom thereof to a carbonyl (C=O) radical thus forming a C₁₋₆alkoxycarbonyl or haloC₁₋₆alkoxycarbonyl radical. Suitable examples of such esterified carboxy groups include, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and *tert*-butoxycarbonyl.

As used herein, the term "fused 9 or 10 membered heterobicyclic ring system" means a 5,6-, 6,5- or 6,6-fused ring system wherein one or both rings contain ring heteroatoms. The ring system is preferably aromatic or partially saturated, thus the ring system preferably comprises an aromatic 6-membered ring fused to a 5-or 6-membered ring which may be unsaturated, partially saturated or saturated. When the ring system contains more than one ring heteroatom at least one such heteroatom is nitrogen. It will be appreciated that where one of the ring heteroatoms is a nitrogen atom, such heteroatom may be at the bridgehead position of the fused ring system. It will also be appreciated that where one of the ring heteroatoms in a saturated ring is sulfur, such heteroatom may be oxidized to a S(O) or S(O)₂ moiety. Likewise, any carbon atom in a saturated ring may be oxidized to a C=O moiety.

Suitable examples of a "fused 9 or 10 membered heterobicyclic ring system" include isoquinolinyl, quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazole, pyridopyridazinyl, pyridopyrimidinyl, pyridopyrazinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, pyrrolopyridazinyl, furopyridazinyl, thienopyridazinyl, pyrrolopyrimidinyl, furopyrimidinyl, thienopyrimidinyl, pyrrolopyrazinyl, fuopyrazinyl, thienopyrazinyl, imidazopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, isoxazolopyridinyl, thiazolopyridinyl, isothiazolopyridinyl, imidazopyridazinyl, pyrazolopyridazinyl, oxazolopyridazinyl, isoxazolopyridazinyl, thiazolopyridazinyl, isothiazolopyridazinyl, imidazopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl, isoxazolopyrimidinyl, thiazolopyrimidinyl, isothiazolopyrimidinyl, imidazopyrazinyl, pyrazolopyrazinyl, oxazolopyrazinyl, isoxazolopyrazinyl, thiazolopyrazinyl, isothiazolopyrazinyl, triazolopyridinyl, benzotriazolyl, quinolinonyl, isoquinolinonyl, dihydroquinolinonyl, dihydroisoquinolinonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroquinazolinonyl, dihydrobenzoxainonyl, dihydrobenzothiadiazine oxide and dihydrobenzothiadiazine dioxide.

In a further aspect of the present invention, the compounds of formula (I) may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.

For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The salts may be formed by conventional means, such as by reacting the free base form of the compound of formula (I) with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

The present invention also includes within its scope N-oxides of the compounds of formula (I) above. In general, such N-oxides may be formed on any available nitrogen atom. The N-oxides may be formed by conventional means, such as reacting the compound of formula (I) with oxone in the presence of wet alumina.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation
5 *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.

10 The compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, the compounds of formula (I) may also exist in tautomeric forms and the
15 invention includes within its scope both mixtures and separate individual tautomers.

It will be appreciated that the preferred definitions of the various substituents recited herein may be taken alone or in combination and, unless otherwise stated, apply to the generic formula for compounds of the present
20 invention as well as to the preferred classes of compound represented by formulae (Ia), (Ib), (Ic), (Id) and (Ie).

The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier or excipient.

25 Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by
30 inhalation or insufflation. Oral compositions such as tablets, pills, capsules or wafers are particularly preferred. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums,

and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these pre-formulation compositions as homogeneous, it is meant that the active
5 ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit
10 dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an
15 envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids
20 with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut
25 oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of painful conditions such as those listed below, a
30 suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to 5 g per day, and especially about 20 mg to 2 g day. The compounds may be administered on a regimen of 1 to 4 times per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular

compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

5 The invention further provides a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body. Preferably, said treatment is for a condition which is susceptible to treatment by modulation (preferably antagonism) of VR1 receptors.

The compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation
10 predominates, including chronic and acute pain conditions. Such conditions include rheumatoid arthritis; osteoarthritis; post-surgical pain; musculo-skeletal pain, particularly after trauma; spinal pain; myofascial pain syndromes; headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain;
15 episiotomy pain; burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral
20 nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and contact dermatitis; pain (as well as broncho-constriction and inflammation) due to exposure (e.g. via ingestion, inhalation, or eye contact) of
25 mucous membranes to capsaicin and related irritants such as tear gas, hot peppers or pepper spray; neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; "non-painful" neuropathies; complex regional pain syndromes; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain,
30 such as pain due to spinal cord or brain stem damage, low back pain, sciatica and ankylosing spondylitis; gout; scar pain; irritable bowel syndrome; inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity; respiratory diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma and

rhinitis, including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis; autoimmune diseases; and immunodeficiency disorders.

Thus, according to a further aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity.

The present invention also provides a method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

The present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

According to a further aspect of the present invention, it may be desirable to treat any of the aforementioned conditions with a combination of a compound according to the present invention and one or more other pharmacologically active agents suitable for the treatment of the specific condition. The compound of formula (I) and the other pharmacologically active agent(s) may be administered to a patient simultaneously, sequentially or in combination. Thus, for example, for the treatment or prevention of pain and/or inflammation, a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.),



spinal blocks, gabapentin, pregabalin and asthma treatments (such as β_2 -adrenergic receptor agonists or leukotriene D₄ antagonists (e.g. montelukast).

Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, etodolac, meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilicoxib. Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Suitable anti-migraine agents of use in conjunction with a compound of the present invention include CGRP-antagonists, ergotamines or 5-HT₁ agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.

Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.

In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

According to a general process (A), compounds of formula (I), in which V is NR⁵, may be prepared by the reaction of an amine of formula (II) with a compound of formula (III):



wherein LG is a suitable leaving group such as an alkyl- or arylsulfonyloxy group (e.g. mesylate or tosylate) or a halogen atom (e.g. bromine, chlorine or iodine).

Preferably the leaving group is chlorine, bromine, iodine or triflate, and especially chlorine.

The reaction is conveniently effected under conditions suitable for a Buchwald-Hartwig Cross-Coupling Reaction (for review, see for instance
5 J. F. Hartwig, *Angew. Chem. Int. Ed.*, 1998, 37, 2046-2067). The reaction is effected in the presence of complex of a palladium catalyst with a chelating phosphane ligand.

Suitable palladium catalysts include:
tris(dibenzylideneacetone)dipalladium(0) [Pd₂(dba)₃], Pd(dba)₂, and
10 2'-(dimethylamino)-2-biphenyl palladium (II) chloride.

Suitable chelating phosphane ligands include:
2-(dicyclohexylphosphino)biphenyl, 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl [BINAP], 2,2'-bis(di-*p*-tolylphosphanyl)-1,1'-binaphthyl [Tol-BINAP], propane-1,3-
15 diylbis(diphenylphosphane) [DPPP] and dinorbornylphosphine.


The reaction is also conveniently effected in the presence of a base such as potassium carbonate or, more typically, sodium *tert*-butoxide.

The reaction is conveniently effected at a temperature between 80°C and 140°C, conveniently at about 100°C. Suitable solvents include, for example, *p*-xylene, toluene or dioxane.

20 It will be appreciated that whilst the leaving group in general process (A) is depicted on the compound of formula (III), it may be desirable in certain circumstances to have the leaving group on the Ar₁ intermediate, and for the central heteroaromatic ring to be substituted by the NHR⁵ moiety.

If the heteroaromatic compound of formula (III) is sufficiently electrophilic
25 and the amine of formula (II) sufficiently nucleophilic, formation of the N-aryl bond may be accomplished using a nucleophilic substitution (S_NAr) reaction. This is the case for example where the amine is benzylic and the heteroaromatic compound is electron poor.

Thus, according to a further general process (B), compounds of formula (I)
30 in which Ar₁ comprises a saturated or partially saturated 6-membered ring to which is fused an aromatic 5- or 6-membered ring, and V is NR⁵, may be prepared by the reaction of a compound of formula (III) with an amine of formula (V):



(V)

wherein -A-B- represents a 3- or 4-atom chain that completes the aromatic 5- or 6-membered ring, said chain containing between 1 and 4 (preferably 1 or 2)

heteroatoms selected from N, O and S. Aptly, -A-B- represents:

(a) $-\text{CH}=\text{CH}-\text{CH}=\text{N}-$,

(b) $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$,

(c) $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$,

(d) $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$,

(e) $-\text{CH}=\text{CH}-\text{NH}-$,

(f) $-\text{CH}=\text{N}-\text{NH}-$,

(g) $-\text{N}=\text{CH}-\text{NH}-$, and

(h) $-\text{CH}=\text{CH}-\text{O}-$;

and R^1 , where present, may be on either or both of the rings of the heterobicyclic ring system.

The reaction may be effected in the presence of a base, if desired, and a suitable solvent such as dimethylacetamide, and is generally carried out at an elevated temperature, for example, between 80°C and 140°C , conveniently at about 100°C .


It will be appreciated that a similar nucleophilic substitution reaction may be used for the preparation of compounds wherein V is an oxygen or sulfur atom, using an alcohol or thiol instead of the amine of formula (V). For the preparation of such ethers or thioethers, a suitable base will be required.

Compounds wherein V is a sulfur atom may be oxidized to corresponding compounds wherein V is SO or SO_2 using conventional methodology, for instance, oxone and wet alumina.


Further details of suitable procedures will be found in the accompanying Examples.

Compounds of formulae (II) and (V) are either known compounds or may be prepared by conventional methodology well known to one of ordinary skill in the art using, for instance, procedures described in the accompanying Examples, or by alternative procedures which will be readily apparent.

- 5 Compounds of formula (III) in which W is N, X is CH and Y is N (i.e. pyrimidines) may be prepared by the reaction of a compound of formula (VI) with a compound of formula (VII):



(VI)




(VII)

10

- wherein LG is as previously defined and R⁴⁰ is B(OH)₂ or Sn(alkyl)₃, for example Sn(methyl)₃ or Sn(n-butyl)₃. Where R⁴⁰ is B(OH)₂, the reaction is conveniently effected under conditions suitable for a Suzuki Coupling Reaction (for review, see for instance A. Suzuki, *Pure Appl. Chem.*, 1991, 63, 419-422), for example, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0), (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium or dichloro-(1,4-bis(diphenylphosphino)butane)palladium, in a suitable solvent such as an ether, for example, dimethoxyethane or dioxane or an aromatic hydrocarbon, for example toluene, at an elevated temperature. Where R⁴⁰ is Sn(alkyl)₃, the reaction is conveniently effected under conditions suitable for a Stille Coupling Reaction (for review, see for instance J. K. Stille, *Angew. Chem. Int. Ed.*, 1986, 25, 508-524), for example, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or bis(triphenylphosphine)palladium (II) chloride, in a suitable solvent such as an ether, for example dioxane, or an aromatic hydrocarbon, for example, toluene, at an elevated temperature.

25


Compounds of formula (III) in which W is N, X is CH and Y is CH (i.e. pyridines) may be prepared by the reaction of a compound of formula (VIII)



(VIII)

with a reagent suitable for the introduction of a leaving group. For instance,
 when LG is chlorine, by reaction with phosphorous oxychloride at an elevated
 5 temperature.


Similarly, compounds of formula (III) in which W is N, X is N and Y is CH
 (i.e. pyridazines) may be prepared by the reaction of a compound of formula (IX)




(IX)

10 with a reagent suitable for the introduction of a leaving group. For instance,
 when LG is chlorine, by reaction with phosphorous oxychloride at an elevated
 temperature.

Compounds of formulae (VIII) and (IX) may be prepared by reaction of a
 15 compound of formula (VII) with a compound of formula (X) or (XI), respectively:



(X)



(XI)


20 using, for example, the Suzuki Coupling or Stille Coupling reaction conditions
 described above.

It will be appreciated that whilst the leaving group in the above coupling
 reactions is depicted on the compounds of formulae (VI), (X) and (XI), it may be

desirable in certain circumstances to have the leaving group on the Ar₂ intermediate, and for the central heteroaromatic ring to be substituted by the B(OH)₂ or Sn(alkyl)₃ moiety.

5 Compounds of formulae (VI), (X) and (XI) are either known compounds or may be prepared by conventional methodology well known to one of ordinary skill in the art using, for instance, procedures described in the accompanying Examples, or by alternative procedures which will be readily apparent.

10 Trisubstituted pyridines of formula (III) in which W is N, X is CH and Y is CH, and R² is other than hydrogen may be prepared using an iridium catalysed borylation reaction of a 2,6-disubstituted pyridine, or a method analogous thereto, as depicted in Scheme 1:



Scheme 1

15

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

25 The following non-limiting Examples serve to illustrate the preparation of compounds of the present invention. The structures of the products of the following Descriptions and Examples were in most cases confirmed by ¹H NMR.

Description 1**3-Methyl-5-nitroisoquinoline**

3-Methylisoquinoline (2.14 g, 14.9 mmol) was added portionwise to ice-cooled concentrated H_2SO_4 (10 ml) keeping the internal temperature below 10 °C.

5 A nitrating mixture of concentrated H_2SO_4 (2 ml) and fuming nitric acid (2 ml) was then added dropwise keeping the internal temperature below 15 °C. After stirring for 30 minutes, TLC indicated reaction was complete. The acid was neutralized by adding the mixture to an excess of 4N aqueous NaOH (180 ml) with ice-cooling. The mixture was extracted with dichloromethane (2 x 150 ml),
10 then dried (Na_2SO_4) and evaporated to give the crude product (2.69 g) as a yellow solid. Flash column chromatography using as eluant 5% methanol in dichloromethane gave a pure sample of the title compound (660 mg) and a sample (1.95 g) containing ca. 10% of the 8-nitro isomer.

15

Description 2**3-Methylisoquinolin-5-amine**

3-Methyl-5-nitroisoquinoline (Description 2; 660 mg, 3.51 mmol) was dissolved in MeOH (30 ml) and PtO_2 catalyst (120 mg) was added. The mixture was stirred for 1 hour 45 minutes under a balloon of hydrogen, then the catalyst was filtered
20 off, washing with more methanol. The filtrate was evaporated and purified by flash column chromatography using as eluant 5% methanol in dichloromethane to give the title compound (250 mg). m/z (ES^+) 159 ($\text{M} + \text{H}^+$).

Description 3

25

1-Methyl-5-nitroisoquinoline

Prepared by nitration of 1-methylisoquinoline according to the procedure of Description 1.

Description 4

30

1-Methylisoquinolin-5-amine

Prepared by reduction of 1-methyl-5-nitroisoquinoline (Description 3) according to the procedure of Description 2.

Description 5**5,6,7,8-Tetrahydroisoquinolin-5-amine**

To a solution of 7,8-dihydroisoquinolin-5-(6H)-one oxime [*Synth. Commun.*, 26(12), p2305-2308, (1996)] (1 g, 6.2 mmol) in ethanol (20 ml) and ethyl acetate (1 ml) was added 10% palladium on carbon (250 mg). The resulting slurry was stirred under a hydrogen balloon at room temperature for 20 hours. The catalyst was removed by filtration and the solvent evaporated to give the title compound as a brown oil (953 mg, 100%). m/z (ES⁺) 149 (M + H⁺).

10

Description 6**2,4-Difluoro-6-methoxybenzaldehyde**

To a solution of 3,5-difluoroanisole (25 g; 175 mmol) in dichloromethane (150 ml) cooled at 0°C was added titanium tetrachloride (30.7 ml; 280 mmol). To this mixture was added dropwise over 10 minutes dichloromethyl methylether (15.8 ml; 175 mmol), and after complete addition the mixture was stirred at room temperature for 1 hour. The reaction was poured onto ice/water (500 ml) and extracted with DCM (3 x 300 ml). The combined DCM layers were washed with water (500 ml), saturated NaCl (200 ml), dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica - eluting with a gradient rising from 15% Et₂O in isohexanes rising to 30% Et₂O in isohexanes to give the title compound (11.2 g, 37%) as a white solid.

15
20**Description 7****2,4-Difluoro-6-hydroxybenzaldehyde**

To a solution of 2,4-difluoro-6-methoxybenzaldehyde (Description 6, 11.2 g; 77.8 mmol) in anhydrous dichloromethane (500 ml) cooled at -78°C was added boron tribromide (9.47 ml; 85.58 mmol) dropwise over 10 minutes. After complete addition the mixture was allowed to warm to room temperature and stirred overnight. The mixture was poured onto ice/water (1 litre) and extracted with DCM (3 x 400 ml). The combined organic layers were washed with water (1 litre), saturated NaCl (500 ml), dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica elution with 10% diethyl ether/ isohexanes to give the title compound (9.2 g, 75%) as an orange oil.

25
30

Description 8

2,4-Difluoro-6-prop-1-ynylbenzaldehyde

To an ice-bath cooled mixture of 2,4-difluoro-6-hydroxybenzaldehyde (Description 7, 9.20 g; 58.2 mmol) and triethylamine (8.92 ml; 64.02 mmol) in anhydrous dichloromethane (100 ml) was added dropwise over 10 minutes trifluoromethanesulfonic anhydride (11.75 ml; 69.84 mmol) and the resulting mixture stirred at room temperature for 1 hour. The mixture was washed with water (300 ml), and the aqueous phase extracted with DCM (100 ml). The combined organic layers were washed with saturated NaCl (100 ml), dried over Na₂SO₄, filtered through a 1 inch plug of silica and evaporated. The residue (14.4 g; 49.6 mmol) and triethylamine (10.37 ml; 74.4 mmol) in anhydrous N,N-dimethylformamide (80 ml) contained within a large (200 ml capacity) sealed tube was cooled to -78°C and propyne gas bubbled through until the volume had increased by approx 10 ml. To this mixture was added Pd(PPh₃)₂Cl₂ (1.74 g; 2.48 mmol) and CuI (449 mg; 4.96 mmol), the lid was put in place and the tube allowed to reach room temperature. The reaction was stirred for 2 hours after which TLC showed reaction was complete. The mixture was poured onto water (500 ml) and extracted with EtOAc (3 x 150 ml); the combined EtOAc layers were washed with water (3 x 400 ml), saturated NaCl (150 ml), dried over Na₂SO₄, filtered through a 1 inch plug of silica and evaporated to give the title compound (8.7g, 97%).

Description 9

6,8-Difluoro-3-methylisoquinoline

A mixture of 2,4-difluoro-6-prop-1-ynylbenzaldehyde (Description 8, 8.7 g; 48.8 mmol) and 2.0M ammonia in methanol (244 ml; 488 mmol) were heated together at 80°C in a Parr apparatus (approx 35psi achieved) for 5 hours. The cooled mixture was evaporated and the residue purified by column chromatography on silica -elution with 100% dichloromethane to give the title compound (5.2 g, 59%) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 2.69 (3 H, s), 6.93-6.99 (1 H, m), 7.13 (1 H, dd, *J* 9.1 and 1.4), 7.44 (1 H, br s), 9.40 (1 H, br s).

Description 10**6,8-Difluoro-3-methylisoquinolin-5-amine**

To an ice-bath cooled solution of 6,8-difluoro-3-methylisoquinoline (Description 9, 1.2 g; 5.35 mmol) in conc. sulfuric acid (7.5 ml) was added dropwise a mixture of fuming nitric acid (1 ml) and conc. sulfuric acid (1 ml) and the resulting mixture stirred at 0°C for 30 minutes. Poured onto ice/water (100 ml) and basified by the portionwise addition of NaHCO₃, then extracted with EtOAc (3 x 100 ml). The combined EtOAc layers were flushed with nitrogen and a spatula end of 5% palladium on carbon added and the reaction was stirred under a balloon of hydrogen for 3 hours. The catalyst was removed by filtration and the filtrate evaporated. The residue was purified by column chromatography on silica elution with 1% MeOH in DCM + 0.5% NH₄OH to give the title compound (930 mg, 89%).

Description 11**3-Methyl-7-(trifluoromethyl)isoquinolin-5-amine**

Prepared using 2-hydroxy-5-trifluoromethylbenzaldehyde [see WO 99/62902-A1] in place of 2,4-difluoro-6-hydroxybenzaldehyde according to the procedures of Descriptions 8, 9, and 10 respectively.

Description 12**2-Fluoro-6-prop-1-ynylbenzaldehyde**

A mixture of 2-bromo-6-fluorobenzaldehyde [see *Tetrahedron Letters* (1992), 33(49), 7499-7502] (4.0 g; 19.7 mmol) and triethylamine (4.12 ml; 29.5 mmol) in anhydrous N,N-dimethylformamide (75 ml) contained within a large (200 ml capacity) sealed tube was cooled to -78°C and propyne gas bubbled through until the volume had increased by approx 10 ml. To this mixture was added Pd(PPh₃)₂Cl₂ (0.69 g; 0.99 mmol) and CuI (180 mg; 1.97 mmol), the lid was put in place and the tube allowed to reach room temperature and stir for 4 hours after which TLC showed the reaction was complete. The mixture was poured onto water (500 ml) and extracted with EtOAc (3 x 150 ml). The combined EtOAc layers were washed with water (3 x 400 ml), saturated NaCl (150 ml), dried over Na₂SO₄, filtered through a 1 inch plug of silica and evaporated to give the title compound (3.2 g, 100%).

Description 13**8-Fluoro-3-methylisoquinolin-5-amine**

Prepared using 2-fluoro-6-prop-1-ynylbenzaldehyde (Description 12) in place of
5 2,4-difluoro-6-prop-1-ynylbenzaldehyde according to the procedures of
Descriptions 9 and 10 respectively.

Description 14**(2-Bromo-4-fluorophenyl)methanol**

10 To a solution of 2-bromo-4-fluorobenzoic acid (20g; 91mmol) in anhydrous THF
(300 ml) at -10°C was added dropwise borane tetrahydrofuran complex (1.0M soln
in THF) (136.5ml; 136.5mmol). After complete addition the reaction was allowed
to stir at room temperature for 4 hours. The reaction was quenched by the
dropwise addition of water (20 ml). To the mixture was added saturated K₂CO₃
15 (200 ml) and water (300 ml). The organic layer was separated and the aqueous
extracted with Et₂O (2 x 300 ml). The combined organics were washed with
water (2 x 500 ml), saturated NaCl (200 ml), dried over Na₂SO₄, filtered and
evaporated to give the title compound (18g, 96%) as a white solid.

20

Description 15**2-Bromo-4-fluorobenzaldehyde**

To a -78°C cooled solution of oxalyl chloride (8.43 ml; 96.58 mmol) in anhydrous
dichloromethane (300 ml) was added dropwise dimethyl sulfoxide (13.71 ml;
193.16 mmol). The mixture was stirred at -78°C for 5 minutes then a solution of
25 (2-bromo-4-fluorophenyl)methanol (Description 14, 18 g; 87.8 mmol) in anhydrous
dichloromethane (150 ml) was added slowly. The resulting mixture was stirred
at -78°C for 15 minutes then triethylamine (36.71 ml; 263.4 mmol) was added and
the mixture allowed to warm to room temperature over 1 hour. The mixture was
washed with water (2 x 500 ml), saturated NaCl (200 ml), dried over Na₂SO₄,
30 filtered through a 2 inch plug of silica gel and evaporated to give the title
compound (16 g, 89%) as a white solid.

Description 16

6-Fluoro-3-methylisoquinolin-5-amine

Prepared using 2-bromo-4-fluorobenzaldehyde (Description 15) in place of 2-bromo-6-fluorobenzaldehyde according to the procedures of Descriptions 12, 9,
5 and 10 respectively.

Description 17

1-Methyl-5-nitroquinolinium iodide

5-nitroquinoline (4g; 30mmol) was melted at 85 °C, prior to addition of dimethyl
10 sulfate (2.2ml, 30mmol), and the resulting mixture was stirred at this
temperature for 1.5 hours. The yellow gel was dissolved in water (35 ml) and
cooled to room temperature. A saturated aqueous solution of potassium iodide
(7.63g, 45.9mmol) was added, and the resulting orange precipitate was filtered,
15 washing the residue with chilled water. After drying under vacuum at 60 °C, for
2 hours, the brick-red solid was used in the next step without purification.

Description 18

1-Methyl-5-nitroquinolin-2(1H)-one

1-Methyl-5-nitroquinolinium iodide (Description 17, 3.53g, 11.2mmol), and
20 potassium hexacyanoferrate(III) (8.11g; 24.7mmol) were suspended in water (ca.
30 ml) and THF (ca 30 ml), and the mixture was basified to pH 14 with 4N NaOH
(aq), and stirred for a further 48 hours. After concentrating to dryness and the
residue was partitioned between DCM / water and filtered through Celite™,
25 washing the filter pad with DCM (200 ml) and water (100 ml). The organic phase
was dried over sodium sulfate and concentrated to give a dark brown oil.
Purification by flash chromatography gave a pale brown solid. (1.15g, 50%).
 m/z (ES⁺) 205 (M + H⁺).

Description 19

5-Amino-1-methyl-3,4-dihydroquinolin-2(1H)-one

1-Methyl-5-nitroquinolin-2(1H)-one (Description 18, 200mg, 0.98mmol) was
dissolved in acetic acid (25 ml) and hydrogenated over PtO₂ (11mg) at 60 psi. The
catalyst was removed by filtration, and the filtrate was concentrated to give a
colourless gel, which was partitioned between CHCl₃ (30 ml) / saturated aqueous

NaHCO₃ (30 ml). The aqueous phase was extracted with CHCl₃ (3x 30 ml), dried (Na₂SO₄) and concentrated under reduced pressure to give a white solid (120 mg, 70%). *m/z* (ES⁺) 177 (M + H⁺).

5

Description 20

5-Amino-1-methylquinolin-2(1H)-one

1-Methyl-5-nitroquinolin-2(1H)-one (Description 18, 0.42g, 2.06mmol) and tin(II) chloride dihydrate (2.09g, 9.26mmol) were suspended in ethanol (20 ml), and the mixture was heated to reflux for 16 hours. The volatiles were removed under reduced pressure and the residue was suspended in water (30 ml) and the pH was adjusted to 8 with 4M NaOH (aq). The mixture was extracted with chloroform (4 x 50ml), the combined organic extracts were dried (Na₂SO₄) and concentrated to give a cream-colored solid (0.32g, 89%). *m/z* (ES⁺) 175 (M + H⁺).

15

Description 21

1-Methyl-4-nitro-1H-indazole and 2-methyl-4-nitro-2H-indazole

To a solution of 4-nitro indazole [WO 01/35947-A2] (5.0 g, 31 mmol) in dimethylformamide at 0 °C was added sodium hydride (1.34 g of a 60% dispersion in oil, 34 mmol). The mixture was stirred at room temperature for 10 minutes. Iodomethane (2.28 ml, 37 mmol) was added and the reaction stirred at room temperature for 90 minutes. Water (500 ml) was added and the reaction extracted into ethyl acetate (3 x 200 ml). The combined organic layers were washed with water (2 x 200 ml) then dried (Mg₂SO₄) and evaporated. Trituration overnight in dichloromethane / hexane gives 0.97 g of pure 1-methyl-4-nitro-1H-indazole. The remaining solution was condensed and purified by column chromatography on silica eluting with 40-20 % hexane in dichloromethane to give additional 1-methyl-4-nitro-1H-indazole (1.30 g, total 2.27 g, 42 %) as the less polar product ¹H NMR (360 MHz, CDCl₃) 4.18 (3H, s), 7.52 (1H, t, *J* 8.0), 7.77 (1H, d, *J* 8.4), 8.15 (1H, d, *J* 7.7), 8.61 (1H, s); and as the more polar, 2-methyl-4-nitro-2H-indazole (1.50 g, 28 %). ¹H NMR (400 MHz, CDCl₃) 4.32 (3H, s), 7.40 (1H, t, *J* 8.0), 8.07 (1H, d, *J* 8.6), 8.18 (1H, d, *J* 7.6), 8.55 (1H, s).

Description 22**1-Methyl-1*H*-indazol-4-amine**

To a solution of 1-methyl-4-nitro-1*H*-indazole (Description 21, 0.97 g, 5.5 mmol) in ethanol (50 ml) was added catalytic 10 % palladium on carbon. The resulting
5 slurry was stirred under a balloon of hydrogen for 2 hours. The catalyst was removed by filtration and the solvent evaporated and the product azeotroped with toluene to give the title compound as a pale brown solid (0.78 g, 96 %).
m/z (ES⁺) 148 (M + H⁺).

10

Description 23**2-Methyl-2*H*-indazol-4-amine**

Prepared from 2-methyl-4-nitro-2*H*-indazole (Description 21) according to the procedure of Description 22. *m/z* (ES⁺) 148 (M + H⁺).

15

Description 24**4-Nitro-1-{{2-(trimethylsilyl)ethoxy}methyl}-1*H*-indazole**

To a solution of 4-nitro indazole (2.55 g, 15.6 mmol) in anhydrous dimethylformamide (20ml) at room temperature was added sodium hydride (902 mg, 37.6 mmol, 2.4 eq, 60% dispersion in oil) portionwise. This was allowed
20 to stir at room temperature for 10 minutes. 2-(Chloromethoxy)ethyl-trimethylsilane (3.3 ml, 18.8 mmol, 1.2 eq) was added and the reaction stirred at room temperature for a further 90 minutes. Water (30 ml) was added and the reaction extracted into diethyl ether (2 x 50 ml). The combined organic layers were washed with brine (2 x 50 ml), the layers separated and the organic layer
25 dried over MgSO₄, filtered and evaporated. The resulting oil was purified by column chromatography on silica eluting with 20% ethyl acetate in isohexane, to give 4-nitro-1-{{2-(trimethylsilyl)ethoxy}methyl}-1*H*-indazole (1.74 g, 38%) as the less polar product and 4-nitro-2-{{2-(trimethylsilyl)ethoxy}methyl}-2*H*-indazole (1.93 g, 42%) as the more polar product. ¹H NMR – 1-Substituted isomer -
30 (360 MHz, CDCl₃) δ 0.00 (9H, s), 0.94 (2H, t, *J* 8.4), 3.63 (2H, t, *J* 8.2), 5.89 (2H, s), 7.62 (1H, t, *J* 8.0), 8.03 (1H, d, *J* 8.3), 8.26 (1H, d, *J* 7.7), 8.71 (1H, s).

Description 25**1-{{2-(Trimethylsilyl)ethoxy}methyl}-1*H*-indazol-4-amine**

To a solution of 4-nitro-1-{{2-(trimethylsilyl)ethoxy}methyl}-1*H*-indazole (Description 24, 1.74 g, 5.9 mmol) in ethanol (25 ml) was added 10% palladium on carbon (190 mg). The resulting slurry was hydrogenated at 50 psi for 1 hour. The reaction was filtered and the solvent evaporated to give the title compound as a brown oil (1.55 g, 99% yield). m/z (ES⁺) 264 (M + H⁺)

Description 26**Methyl 5-fluoro-2-methyl-3-nitrobenzoate**

To a solution of 5-fluoro-2-methyl benzoic acid (62.6 g; 406 mmol) in conc. sulfuric acid (500 ml) cooled at -10°C was added dropwise a mixture of fuming nitric acid (20.6 ml) and conc. sulfuric acid (94 ml). After complete addition the mixture was stirred at 0°C for 1 hour. Poured onto ice/water (1.5 litre) and stirred for 10 minutes then extracted with EtOAc (3 x 500 ml), the combined EtOAc layers were washed with water (800 ml), saturated NaCl (500 ml), dried over Na₂SO₄, filtered and evaporated. The residue was dissolved in methanol (1 litre) and conc. HCl (15 ml) added, and the resulting mixture heated at reflux overnight. The cooled reaction mixture was evaporated and the residue partitioned between DCM (700 ml) and saturated NaHCO₃, the organic layer was separated and washed with saturated NaCl (200 ml), dried over Na₂SO₄, filtered and evaporated to give the title compound (51.5 g, 59%) as an oil.

Description 27**Methyl 3-amino-5-fluoro-2-methylbenzoate**

To a nitrogen flushed solution of methyl 5-fluoro-2-methyl-3-nitrobenzoate (Description 26, 51.58 g; 242 mmol) in methanol (400 ml) was added 5% Palladium on carbon (3 g), and the resulting mixture hydrogenated on a Parr apparatus at 50psi until hydrogen uptake ceased (approx 45 minutes). The catalyst was removed by filtration and the filtrate evaporated to dryness to give the title compound (39.5 g, 89%) as a solid.

Description 28**Methyl 6-fluoro-1*H*-indazole-4-carboxylate**

To a mixture of methyl 3-amino-5-fluoro-2-methylbenzoate (Description 27, 39.5 g; 216 mmol) and ammonium tetrafluoroborate (30.12 g; 287.3 mmol) in a mixture of water (400 ml) and conc. hydrochloric acid (60 ml) cooled in an ice bath, was added a solution of sodium nitrite (14.9 g; 216 mmol) in water (60 ml). After complete addition the mixture was stirred for 40 minutes. The precipitate was filtered and washed with diethyl ether. This solid was then added in one portion to a mixture of potassium acetate (23.32 g; 237.6 mmol), and 18-crown-6 (1.71 g; 6.48 mmol) in chloroform (800 ml), and the resulting mixture stirred at room temperature for 1 hour. Water (500 ml) was added and the layers separated; the aqueous was further extracted with dichloromethane (2 x 300 ml), and the combined organic layers washed with water, saturated NaCl, dried over Na₂SO₄, filtered and evaporated. The residue was triturated with iso-hexanes, filtered and dried to give the title compound (11.5 g, 27%) as an orange solid.

Description 29**Methyl 6-fluoro-1-methyl-1*H*-indazole-4-carboxylate**

To a solution of methyl 6-fluoro-1*H*-indazole-4-carboxylate (Description 28, 5.00 g; 25.8 mmol) in anhydrous N,N-dimethylformamide (75 ml) was added sodium hydride (60% dispersion in oil) (1.2 g; 30.96 mmol) followed 5 minutes later by iodomethane (1.93 ml; 30.96 mmol), and the resulting mixture stirred at room temperature overnight. Poured into water (500 ml) and extracted with EtOAc (3 x 100 ml); the combined EtOAc layers were washed with water (3 x 200 ml), saturated NaCl (100 ml), dried over Na₂SO₄, filtered and evaporated. The residue was purified by column chromatography on silica eluting with a gradient rising from 25% EtOAc in isohexanes to 50% EtOAc in isohexanes to give the title compound (2.62g, 48%).

Description 30**6-Fluoro-1-methyl-1*H*-indazole-4-carboxylic acid**

To a solution of methyl 6-fluoro-1-methyl-1*H*-indazole-4-carboxylate (Description 29, 2.62 g; 12.6 mmol) in methanol (50 ml) was added a solution of sodium hydroxide (2.52 g; 63 mmol) in water (20 ml) and the resulting mixture heated at

reflux overnight. The mixture was cooled and the methanol removed by evaporation. Water (100 ml) was added and then the mixture was acidified by the addition of conc. HCl, and extracted with EtOAc (3 x 75 ml); the combined EtOAc layers were washed with water (100 ml), saturated NaCl (50 ml), dried
5 over Na₂SO₄, filtered and evaporated to give the title compound (1.8 g, 74%) as a yellow solid.

Description 31

tert-Butyl 6-fluoro-1-methyl-1H-indazol-4-ylcarbamate

10 To a solution of 6-fluoro-1-methyl-1H-indazole-4-carboxylic acid (Description 30, 2.33g; 12 mmol) in anhydrous toluene (50 ml) was added triethylamine (1.84 ml; 13.2 mmol) followed by diphenylphosphoryl azide (2.85 ml; 13.2 mmol) and the resulting mixture heated to reflux for 1 hour. After this time 2-methyl-2-propanol (1.7 ml; 18.0 mmol) was added and heating continued overnight. The
15 mixture was cooled and evaporated, and the residue purified by column chromatography on silica elution with 50% diethyl ether in isohexanes to give the title compound (1.82 g, 57%).

Description 32

20 6-Fluoro-1-methyl-1H-indazol-4-amine

A solution of *tert*-butyl 6-fluoro-1-methyl-1H-indazol-4-ylcarbamate (Description 31, 1.82 g; 6.86 mmol) in anhydrous methanol (50 ml) was saturated with hydrogen chloride gas and left standing until HPLC showed complete reaction. The mixture was evaporated and the residue partitioned between saturated
25 NaHCO₃ and DCM. The organic layer was separated and washed with saturated NaCl, dried over Na₂SO₄, filtered and evaporated to give the title compound (940 mg, 83%).

Description 33

30 1-Methyl-6-(trifluoromethyl)-1H-indazol-4-amine

Prepared from 2-methyl-5-trifluoromethyl benzoic acid in place of 5-fluoro-2-methyl benzoic acid using analogous procedures to those described in Descriptions 26 to 32 respectively.

Description 34

Ethyl 2-cyanonicotinate

To ethyl 2-chloronicotinate (15.0g ; 81 mmol) in anhydrous N,N-dimethylacetamide (75 ml) was added zinc cyanide (5.71 g; 48.6 mmol),
5 Pd₂(dba)₃ (742 mg; 0.81 mmol), zinc (636 mg; 9.72 mmol), and
1,1'-bis(diphenylphosphino)ferrocene (898 mg; 1.62 mmol), and the resulting
mixture heated at 120°C for 1 hour. The mixture was cooled to room temperature
and partitioned between water (300 ml) and diethyl ether (150 ml), the mixture
was filtered through Celite™ and the phases separated. The aqueous phase was
10 further extracted with diethyl ether (2 x 100 ml), the combined diethyl ether
layers washed with saturated NaCl, dried over Na₂SO₄, filtered and evaporated
to give the title compound (14.26 g, 100%).

Description 35

15 [3-(Ethoxycarbonyl)pyridin-2-yl]methanaminium chloride

To a nitrogen flushed solution of ethyl 2-cyanonicotinate (Description 34, 14.27 g;
81 mmol) and conc. HCl (15 ml) was added 10% Palladium on carbon (2 g), and
the resulting mixture hydrogenated at 50 psi until HPLC and MS indicated
complete conversion (approx 2 days). The catalyst was removed by filtration and
20 the filtrate evaporated to give the title compound (17.55 g, 100%).

Description 36

Ethyl imidazo[1,5-a]pyridine-8-carboxylate

Acetic anhydride (38.21 ml; 405 mmol) and formic acid (15.28 ml; 405 mmol)
25 were mixed together at 60°C for 2 hours then allowed to cool to room
temperature. To this mixture was added [3-(ethoxycarbonyl)pyridin-2-
yl]methanaminium chloride (Description 35, 17.55 g; 81 mmol), and the resulting
mixture stirred at room temperature for 1 hour, then heated at 35°C for 3 hours.
The mixture was cooled to 5°C and neutralised with 0.88 ammonia solution and
30 then extracted with dichloromethane (3 x). The combined dichloromethane layers
were washed with water, saturated NaCl, dried over Na₂SO₄, filtered and
evaporated. The residue was purified by column chromatography on silica
eluting with 2% MeOH in DCM + 0.5% NH₄OH to give the title compound
(8.67 g, 56%).

Description 37**Imidazo[1,5-*a*]pyridine-8-carboxylic acid**

Ethyl imidazo[1,5-*a*]pyridine-8-carboxylate (Description 36, 8.67 g; 45.6 mmol)
5 and KOH [1.0M in methanol] (91.2 ml; 91.2 mmol) were mixed together and
heated to reflux for 30 minutes when HPLC indicated the reaction was complete.
The mixture was cooled and evaporated to dryness. Water (50 ml) was then
added, and the mixture acidified with 2N HCl to give a yellow precipitate. The
precipitate was filtered and washed successively with water, ethanol, and diethyl
10 ether to give the title compound (3.1 g, 42%) as a yellow solid.

Description 38**tert-Butyl imidazo[1,5-*a*]pyridin-8-ylcarbamate**

To a suspension of imidazo[1,5-*a*]pyridine-8-carboxylic acid (Description 37, 2.0 g;
15 12.31 mmol) and triethylamine (1.89 ml; 13.54 mmol) in anhydrous toluene
(75 ml) was added diphenylphosphoryl azide (2.92 ml; 13.54 mmol), and the
resulting mixture heated at reflux for 1 hour. To this mixture was added
2-methyl-2-propanol (1.74 ml; 18.47 mmol) and heating continued overnight. The
mixture was cooled and evaporated, and the residue purified by column
20 chromatography on silica elution with 4% MeOH in DCM + 0.5% NH₄OH to give
the title compound (1.85 g, 64%) as a white solid.

Description 39**Imidazo[1,5-*a*]pyridin-8-amine**

25 A solution of *tert*-butyl imidazo[1,5-*a*]pyridin-8-ylcarbamate (Description 38,
1.00 g; 4.29 mmol) in anhydrous methanol (50 ml) was saturated with hydrogen
chloride gas. The mixture was left standing for 2 hours - HPLC indicated
reaction was complete. The mixture was evaporated and the residue basified by
the addition of saturated NaHCO₃. The mixture was extracted with DCM (3 x
30 75 ml), and the combined DCM layers washed with saturated NaCl, (50 ml), dried
over Na₂SO₄, filtered and evaporated to give the title compound (423 mg, 74%) as
a dark solid.

Description 40

tert-Butyl 2-([(4-methylphenyl)sulfonyl]hydrazono)methylpyridin-3-ylcarbamate

To a solution of *tert*-butyl 2-formylpyridin-3-ylcarbamate (4.4 g, 20 mmol)

(*Tetrahedron*, 54, (1998), 6311-6318) in methanol (90 ml) was added

- 5 *p*-toluenesulfonyl hydrazide (3.7 g, 20 mmol). The solution was heated to reflux for 5 minutes and allowed to cool to room temperature. A white solid was seen to precipitate out which was collected by filtration to give the title compound (6.6 g, 85 %).

Description 41

tert-Butyl [1,2,3]triazolo[1,5- α]pyridin-4-ylcarbamate

A solution of the *p*-toluenesulfonyl hydrazone derived from *tert*-butyl

2-formylpyridin-3-ylcarbamate (Description 40, 6.6 g, 17 mmol) in morpholine

(75 ml) was heated at reflux for 90 minutes. The cooled reaction mixture was

- 15 evaporated and the residue partitioned between ethyl acetate (50 ml) and saturated sodium bicarbonate solution (75 ml). The aqueous phase was extracted with ethyl acetate (2x 50 ml). The combined organic extracts were washed with brine (50 ml), dried over MgSO₄, filtered and evaporated. The residue was
- 20 purified by flash column chromatography using eluant system of 1:1 ethyl acetate:hexane to give the title compound (1.1 g, 28%).

Description 42

[1,2,3]Triazolo[1,5- α]pyridin-4-amine

To an ice-cooled solution of *tert*-butyl [1,2,3]triazolo[1,5- α]pyridin-4-ylcarbamate

- 25 (Description 41, 1.1 g, 4 mmol) in dichloromethane (10 ml) was added trifluoroacetic acid (10 ml). The reaction mix was warmed to room temperature and stirred for 2 hours. The reaction mixture was then evaporated and partitioned between saturated sodium bicarbonate solution and ethyl acetate. The organic layer was evaporated to give the title compound (480 mg, 75%).

30

Description 43

2-Chloro-4-[4-(trifluoromethyl)phenyl]pyridine

To a mixture of 4-chloropyridine-N-oxide (5.32 g, 41 mmol) and

4-(trifluoromethyl)phenylboronic acid (9.36 g, 49.3 mmol) in anhydrous

1,2-dimethoxyethane (100 ml) was added tetrakis(triphenylphosphine)palladium (0) (1.5 g, 1.3 mmol) and saturated aqueous sodium carbonate solution (50 ml). Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 100 °C for 15 hours under an atmosphere of nitrogen.

5 The mixture was allowed to cool to room temperature and the solid was filtered off and washed with 1,2-dimethoxyethane (2 x 30 ml). The combined organic layers were evaporated under reduced pressure and triturated with diethyl ether (100 ml). The obtained solid was filtered off and dried on the sinter to give 4-(4-trifluoromethyl)phenylpyridine-N-oxide (8.36 g). This compound was
10 suspended in phosphorous oxychloride (50 ml, 536 mmol) and the mixture was heated at 100 °C for 3 hours. After cooling to room temperature the homogeneous dark solution was evaporated under reduced pressure and repartitioned between chloroform and water (200 ml each). The pH was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate solution and the phases were
15 separated. After two further extractions the combined organic extracts were washed with water and brine and dried over sodium sulfate. After filtration the compound was adsorbed onto silica gel and purified by flash chromatography (10% ethyl acetate-iso-hexane) to yield the title compound (5.5 g, 52 %).

20 **Description 44**

2-Chloro-4-[4-(trifluoromethoxy)phenyl]pyridine

Prepared from 4-chloropyridine-N-oxide and 4-(trifluoromethoxy)phenylboronic acid according to the procedure of Description 43, (0.22 g, 44 %).

25 **Description 45**

2-Chloro-4-[3-(trifluoromethyl)phenyl]pyridine

Prepared from 4-chloropyridine-N-oxide and 3-(trifluoromethyl)phenylboronic acid according to the procedure of Description 43, (1.2 g, 60 %).

30 **Description 46**

2-Chloro-4-phenylpyridine

Prepared from 4-chloropyridine-N-oxide and phenylboronic acid according to the procedure of Description 43, (3.13 g, 45 %).

Description 47**2,6-Dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine**

To a mixture of 2,6-dichloropyridine (3.28 g, 22.2 mmol) and bis(pinacolato)diboron (6.2 g, 24.4 mmol) was added 1,10-phenanthroline (0.24 g, 1.3 mmol) and chloro-1,5-cyclooctadiene iridium (I) dimer (0.44 g, 0.66 mmol) under nitrogen followed by anhydrous 1,2-dichloroethane. Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 100 °C for 15 hours under an atmosphere of nitrogen. The mixture was allowed to cool to room temperature, poured onto diethylether/ 4N sodium hydroxide (50 ml/ 200 ml) and the phases separated. The aqueous phase was acidified with 6N hydrochloric acid and the resulting solid was filtered, washed with water and dried on the sinter to yield the pinacol ester of 2,6-dichloropyridin-4-ylboronic acid (3.5 g, 58 %) as a grey solid.

Description 48**2,6-Dichloro-4-[4-(trifluoromethyl)phenyl]pyridine**

To a mixture of the pinacol ester of 2,6-dichloropyridin-4-ylboronic acid (Description 47, 1.0 g, 3.65 mmol) and 4-iodobenzotrifluoride (2.0 g, 7.35 mmol) in anhydrous dioxane (25 ml) was added (1,1'-bis(diphenylphosphino)ferrocene)-dichloropalladium (0.14 g, 1.91 mmol) and saturated aqueous sodium carbonate solution (4 ml). Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 90 °C for 15 hours under an atmosphere of nitrogen. The mixture was allowed to cool to room temperature and poured onto a mixture of ethyl acetate/ water (100 ml/ 30 ml). The phases were separated and the aqueous phase was extracted two times more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flash chromatography (10% ethyl acetate- iso-hexane) yielded the title compound (0.59 g, 56 %) as a white solid.

Description 49**2,6-Dichloro-4-(pyridin-4-yl)pyridine**

Prepared from the pinacol ester of 2,6-dichloropyridin-4-ylboronic acid
(Description 47) and 4-bromopyridine hydrochloride according to the procedure of
5 Description 48 (4.9 g, 87 %).

Description 50**2-Chloro-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine**

Prepared from 2-chloro-6-methylpyridine and bis(pinacolato)diboron according to
10 the procedure of Description 47 (4.8 g, 78 %).

Description 51**2-Chloro-6-methyl-4-[4-(trifluoromethyl)phenyl]pyridine**

Prepared from the pinacol ester of 2-chloro-6-methylpyridin-4-ylboronic acid
15 (Description 50) and 4-iodobenzotrifluoride according to the procedure of
Description 48 (2.64 g, 97 %).

Description 52**2-Chloro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine**

Prepared from 2-chloro-6-methoxypyridine and bis(pinacolato)diboron according
20 to the procedure of Description 47 (5.2 g, 79 %).

Description 53**2-Chloro-6-methoxy-4-[4-(trifluoromethyl)phenyl]pyridine**

Prepared from the pinacol ester of 2-chloro-6-methoxypyridin-4-ylboronic acid
25 (Description 52) and 4-iodobenzotrifluoride according to the procedure of
Description 48 (2.2 g, 77 %).

Description 54

30 **3-Chloro-5-[4-(trifluoromethyl)phenyl]pyridazine**

To a mixture of 5-chloropyridazin-3(2H)-one [Spanish patent 454136 (1977)]
(2.32 g, 17.8 mmol) and 4-(trifluoromethyl)phenylboronic acid (4.06 g, 21.4 mmol)
in anhydrous dioxane (20 ml) was added (1,1'-bis(diphenylphosphino)ferrocene)-
dichloropalladium (0.8 g, 1.09 mmol) and saturated aqueous sodium carbonate

solution (18 ml). Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 100 °C for 24 hours under an atmosphere of nitrogen. The mixture was allowed to cool to room temperature and poured onto a mixture of ethyl acetate/ ethanol/ water (300 ml/ 30 ml/ 30 ml).
5 The phases were separated and the aqueous phase was extracted two times more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flask column chromatography (50% ethyl acetate- iso-hexane) gave 5-[4-(trifluoromethyl)-phenyl]pyridazin-3(2*H*)-one (0.78 g) which was suspended in phosphorous
10 oxychloride (5 ml, 54 mmol) and the mixture heated at 100 °C for 5 hours. After cooling to room temperature the homogeneous dark solution was evaporated under reduced pressure and repartitioned between chloroform and water (50 ml each). The pH was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate solution and the phases were separated. After two further
15 extractions the combined organic extracts were washed with water and brine and dried over sodium sulfate. After filtration the compound was adsorbed onto silica gel and purified by flash column (50% ethyl acetate-iso-hexane) to yield the title compound (0.56 g, 12 %).

20

Description 55

5-(4-*tert*-Butylphenyl)pyridazin-3(2*H*)-one

A mixture of 5-chloropyridazin-3(2*H*)-one [Spanish patent 454136 (1977)] (2.94 g, 22.5 mmol), 4-*tert*-butylphenylboronic acid (8 g, 44.9 mmol), dioxane (100 ml), 2M aqueous sodium carbonate solution (25 ml) and [1,1'-bis(diphenylphosphino)-
25 ferrocene]dichloropalladium (0.5 g) was degassed (N₂), then heated at 100°C for 18 hours under nitrogen. After cooling to room temperature and standing 24 hours, ethyl acetate (250 ml) was added. The mixture was filtered and the collected solid washed with ethyl acetate to give the title compound 2.36 g. The layers of the filtrate were separated, the aqueous phase extracted with ethyl
30 acetate (100 ml) and the combined organic phases evaporated. Ethyl acetate (100 ml) was added to the residue and the mixture left to stand. A second crop of crystals (2.26 g) was collected and washed with ethyl acetate, giving a combined yield of 4.62 g, 90 %.

Description 56**5-(4-*tert*-Butylphenyl)-3-chloropyridazine**

5-(4-*tert*-Butylphenyl)pyridazin-3(2*H*)-one (Description 55, 2.35 g, 9.53 mmol) was added to phosphorus oxychloride (20 ml) and the mixture heated at 85°C for 1
5 hour. The cooled reaction mixture was cautiously added to ice-water (200 ml) and stirred for 10 minutes. The mixture was then extracted with ethyl acetate (2 x 100 ml) and the combined organic layers washed with 10% aqueous potassium carbonate solution (50 ml), then dried (Na₂SO₄) and evaporated. The residue was
10 purified by flash column chromatography eluting with 15% ethyl acetate – hexane, increasing to 25% ethyl acetate – hexane to give the title compound (2.28 g, 90%).

Description 57**5-(3-Cyanophenyl)pyridazin-3(2*H*)-one**

15 To a mixture of 5-chloropyridazin-3(2*H*)-one [Spanish patent 454136 (1977)] (2.0 g, 15.3 mmol) and 3-cyanophenyl boronic acid (2.71 g, 18.4 mmol) in anhydrous toluene (20 ml) was added dichloro-(1,4-bis(diphenylphosphino)-butane)palladium (0.1 g, 0.16 mmol), and saturated aqueous sodium carbonate solution (5.0 ml) and the mixture was irradiated in a Milestone microwave
20 reactor at 120 °C for 15 minutes. The resulting suspension was filtered and the solid was washed with isopropanol (20 ml) and dried on the sinter to give 5-(3-cyanophenyl)pyridazin-3-one (1.8 g, 50 %) as a yellow solid.

Description 58**3-Chloro-5-(3-cyanophenyl)pyridazine**

25 5-(3-Cyanophenyl)pyridazin-3(2*H*)-one (Description 57, 1.8 g, 9.1 mmol) was suspended in phosphorous oxychloride (15 ml, 12 mmol) and the mixture was heated at 100 °C for 1 hour. After cooling to room temperature the homogeneous dark solution was concentrated under reduced pressure to 1/3 of its original
30 volume poured onto ice-water (250 ml). The pH was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate solution and the resulting solid was filtered, washed with water and dried on the sinter to yield the title compound (1.5 g, 76 %).

Description 59**3,6-Dichloro-5-[4-(trifluoromethyl)phenyl]pyridazine**

4-(Trifluoromethyl)phenylacetonitrile (38.9 g; 210 mmol) was dissolved in dry methanol under nitrogen. Glyoxylic acid monohydrate (29 g, 315 mmol) was added followed by potassium carbonate (74 g, 535 mmol) and the resulting mixture was stirred for 15 hours at room temperature. The resulting solid was filtered, washed with dichloromethane and dried on the sinter to yield an off-white solid which was added at room temperature to a solution of conc. sulfuric acid (30 ml) and formic acid (400 ml). The resulting mixture was then heated with stirring at 110 °C for 3 hours, allowed to cool to room temperature and concentrated under vacuum to 2/3 of the initial volume. It was then poured ice- water (1000 ml) and the resulting solid was filtered off, washed with water and dried on the sinter to yield 35 g of 3-(4-(trifluoromethyl)phenyl)maleic anhydride as an off-white solid.

The crude 3-(4-(Trifluoromethyl)phenyl)maleic anhydride (35 g) was suspended in water (290 ml) and glacial acetic acid (145 ml) was added followed by a solution of hydrazine hydrate (7 ml, 144 mmol) in water (21 ml). After thorough mixing conc. sulfuric acid was added in small portions with external water cooling and the mixture was heated while stirring at 125 °C for 3 hours. After cooling to room temperature the solid was filtered off, washed with water until the pH was neutral and dried on the sinter to yield a grey solid. Phosphorous oxychloride (200 ml, 2.1 mol) was added to the solid and the mixture was heated at 120 °C for 2 hours. After cooling to room temperature the homogeneous dark solution was concentrated under reduced pressure to ½ of its original volume and poured into water (800 ml) while stirring vigorously. The resulting solid was filtered off, washed with water and dried on the sinter to yield a grey solid which was recrystallised from toluene/ iso-hexane (1:1) to yield the title compound as a yellow solid (8.2 g, 13 %).

30

Description 60**3-Chloro-5-(3-methylpyridin-2-yl)pyridazine**

To a mixture of 5-chloropyridazin-3(2H)-one [Spanish patent 454136 (1977)] (0.135 g, 1 mmol) and 2-(tri-n-butylstannyl)-3-methylpyridine (0.42 g, 1.1 mmol) in anhydrous 1,4-dioxane (2 ml) was added tetrakis(triphenylphosphine)-

palladium (0) (0.06 g, 0.051 mmol), copper(I)iodide (20 mg, 0.1 mmol) and lithium chloride (0.13 g, 3.1 mmol) and the mixture was irradiated in a Smith microwave reactor at 160 °C for 15 minutes. The mixture was allowed to cool to room temperature and poured onto a mixture of ethyl acetate/ water (10 ml/ 5 ml). The phases were separated and the aqueous phase was extracted two times more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flash chromatography (ethyl acetate) gave 5-(3-methylpyrid-2-yl)pyridazin-3(2H)-one (0.13 g, 69 %) as a yellow solid which was suspended in phosphorous oxychloride (5 ml, 54 mmol) and the mixture was heated at 100 °C for 1 hours. After cooling to room temperature the homogeneous dark solution was evaporated under reduced pressure and repartitioned between chloroform and water (50 ml each). The pH was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate solution and the phases were separated. After two further extractions the combined organic extracts were washed with water and brine and dried over sodium sulfate. After filtration the compound was adsorbed onto silica gel and purified by flash column (50% ethyl acetate-iso-hexane) to yield the title compound (0.38 g, 54 %).

20

Description 61

5-(4- Methoxyphenyl)pyridazin-3(2H)-one

Five reaction tubes each containing 5-chloropyridazin-3(2H)-one [Spanish patent 454136 (1977)] (100 mg, 0.77 mmol), 4-methoxyphenylboronic acid (230 mg, 1.53 mmol), dioxane (3 ml), 2M aqueous sodium carbonate solution (1 ml) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (20 mg) were irradiated in a microwave reactor at 150 °C for 10 minutes. After cooling to room temperature the mixtures were combined and filtered. The collected solid was washed with water (3 ml), ethyl acetate (5 ml) and ether (5 ml), then dried to give the title compound (724 mg, 93%).

30

Description 62

3-Chloro-5-(4-methoxyphenyl)pyridazine

5-(4- Methoxyphenyl)pyridazin-3(2H)-one (Description 61, 720 mg, 3.56 mmol) was added to phosphorus oxychloride (10 ml) and the mixture heated at 100°C for

16 hours. The cooled reaction mixture was cautiously added to ice-water (250 ml) and stirred for 10 minutes. The mixture was then extracted with dichloromethane (3 x 100 ml) and the combined organic layers washed with 10% aqueous potassium carbonate solution (100 ml), then dried (Na₂SO₄) and
5 evaporated. The residue was purified by flash column chromatography eluting with 5% methanol in dichloromethane to give the title compound (483 mg).

Description 63

5-[2-Fluoro-4-(trifluoromethyl)phenyl]pyridazin-3(2H)-one

10 A mixture of 5-chloropyridazin-3(2H)-one [Spanish patent 454136 (1977)] (1.91 g, 14.6 mmol), bis(pinacolato)diboron (3.89 g, 15.3 mmol), potassium acetate (2.14 g, 21.8 mmol), dioxane (100 ml) and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium (0.4 g) was degassed (N₂), then heated at 90°C for 16 hours under nitrogen. More catalyst (0.45 g) was added and the mixture heated 7 hours
15 more. After cooling to room temperature 4-bromo-3-fluorobenzotrifluoride (4.5 g, 18.5 mmol) was added along with 2M aqueous sodium carbonate solution (35 ml) and a further portion of catalyst (450 mg). The mixture was heated to 115 °C for 24h, then cooled to room temperature, diluted with ethyl acetate (250 ml) and filtered. The layers were separated, the aqueous phase extracted with ethyl
20 acetate (100 ml) and the combined organic layers evaporated. The residue was purified by flash column chromatography eluting with 5% methanol in dichloromethane to give the title compound (795 mg, 21 %).

Description 64

3-Chloro-5-[2-fluoro-4-(trifluoromethyl)phenyl]pyridazine

25 5-[2-Fluoro-4-(trifluoromethyl)phenyl]pyridazin-3(2H)-one (Description 63, 763 mg, 2.96 mmol) was added to phosphorus oxychloride (5 ml) and the mixture heated at 85 °C for 1 hour. The cooled reaction mixture was cautiously added to ice-water (75 ml) and stirred for 10 minutes. The mixture was then extracted
30 with dichloromethane (2 x 50 ml) and the combined organic layers washed with half saturated aqueous sodium bicarbonate solution (50 ml), then dried (Na₂SO₄) and evaporated. The residue was purified by flash column chromatography eluting with 5% methanol in dichloromethane to give the title compound (420 mg, 51 %).

Description 65**5-Chloro-3-(4-fluorophenyl)pyridazine**

To a mixture of 5-chloropyridazin-3(2*H*)-one [Spanish patent 454136 (1977)]
5 (7.33 g, 56 mmol) was suspended in phosphorous oxychloride (55 ml, 594 mmol)
and the mixture was heated at 80 °C for 3 hours. After cooling to room
temperature the homogeneous dark solution was evaporated under reduced
pressure and repartitioned between chloroform and water (50 ml each). The pH
was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate
10 solution and the phases were separated. After two further extractions the
combined organic extracts were washed with water and brine and dried over
sodium sulfate. After filtration the compound was adsorbed onto silica gel and
purified by flash column (10% ethyl acetate-iso-hexane) to yield
3,5-dichloropyridazine (5.6 g, 67 %) as a pale yellow solid. A sample of
15 3,5-dichloropyridazine (0.43 g, 2.9 mmol) was dissolved in tetrahydrofuran
(10 ml) under nitrogen and cooled to -65 °C. 1,2-(Bis(diphenylphosphino)ethane)-
dichloronickel(II) (0.08 g, 0.15 mmol) was added followed by 4-fluorophenylzinc
bromide (11.6 ml of a 0.5 M solution in tetrahydrofuran). The mixture was
warmed to -10 °C over 4 hours and poured onto a mixture of ethyl acetate/ water
20 (30 ml/ 10 ml). The phases were separated and the aqueous phase was extracted
twice with ethyl acetate. The combined organic layers were washed with brine,
dried over sodium sulfate and adsorbed onto silica gel. Purification by flask
column chromatography (10% ethyl acetate- iso-hexane) gave the title compound
(0.35 g, 58 %) as a red solid.

25

Description 66**4-Chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine**

To a slurry of 4,6-Dichloropyrimidine (2g; 13.4 mmol),
4-(trifluoromethyl)phenylboronic acid (3.06 g; 16.1 mmol) and tripotassium
30 phosphate (5.70 g; 26.8 mmol) in 1,4-dioxan (20ml) degassed with nitrogen for 10
minutes was added tetrakis(triphenylphosphine)palladium(0) (0.78g; 0.67mmol).
The reaction mixture was then heated at 100°C for 18 hours. The reaction
mixture was diluted with ethyl acetate and filtered through a pad of Hyflo™.
The filtrate was evaporated under reduced pressure to give an oil. The oil was

taken up in ethyl acetate and washed with brine. The ethyl acetate extracts were then combined, dried (MgSO₄) filtered and evaporated under reduced pressure to give a dark red oil. The oil was purified by flash chromatography eluting with hexane (500ml) hexane/ethyl acetate (10:1) as eluant. The appropriate fractions
5 were combined and evaporated under reduced pressure to give a solid (2.1g) as a mixture of desired product and 4,6-bis-[4-(trifluoromethyl)phenyl]-pyrimidine (9:1).

Description 67

10 4,6-Dichloro-2-methylpyrimidine

A mixture of 4,6-dihydroxy-2-methylpyrimidine (15 g, 120 mmol) and phosphorus oxychloride (150 ml) were heated at reflux overnight. After allowing to cool the reaction mixture was concentrated to ~ 30 ml and then poured onto ice. The reaction mixture was extracted with ethyl acetate (3 x 75 ml). The organic
15 extracts were combined, washed with base, brine, dried over magnesium sulfate, filtered and evaporated to give the title compound (13.4 g, 69%).

Description 68

4-Chloro-2-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine

20 Prepared from 4,6-dichloro-2-methylpyrimidine (Description 67) and 4-(trifluoromethyl)phenylboronic acid according to the procedure of Description 66.

Palladium-catalysed arylation reactions of amines.

25 Couplings of an amine and a heterocyclic halide were, unless otherwise stated, carried out according to one of the two general procedures below. The procedures have been routinely performed on scales of 0.5 mmol up to 10 mmol and representative procedures are described on a 1 mmol scale.

30 **Description 69**

First general procedure for the coupling of amines with heterocyclic chlorides.

An amine (1.2 mmol), a heterocyclic halide (1.0 mmol),
tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol) and
2-(dicyclohexylphosphino)biphenyl (18 mg, 0.05 mmol) were added to a dry flask

under a nitrogen atmosphere. Sodium *t*-butoxide (144 mg, 1.5 mmol) and *para*-xylene (3 ml) were introduced and the reaction mixture degassed by bubbling nitrogen through for 5 minutes. The reaction was heated at 100°C with stirring for 15 hours, then cooled to room temperature. The reaction was
5 partitioned between ethyl acetate (20 ml) and water (5 ml) and the aqueous phase extracted with more ethyl acetate (x2). The combined organic layers were washed with brine dried (Na₂SO₄) and evaporated. The crude mixture was adsorbed onto silica gel, then purified by flash column chromatography. Where required, further purification was achieved by recrystallisation from alcoholic
10 solvents.

Description 70

Second general procedure for the coupling of amines with heterocyclic chlorides.

An amine (1.2 mmol), a heterocyclic halide (1.0 mmol) and sodium *t*-butoxide
15 (144 mg, 1.5 mmol) were added to a dried flask under a nitrogen atmosphere. *para*-xylene or toluene (5 ml) was introduced and the reaction mixture degassed. 2'-(Dimethylamino)-2-biphenyl palladium (II) chloride dinorbornylphosphine complex [see *Angew. Chem.*, 2002, 41, 3668; CAS number 359803-53-5] (2 mol%) was added, the reaction was degassed once more, then heated to 100°C (or 130°C
20 if required) for 18 hours. The reaction was loaded directly onto silica gel and purified by flash column chromatography. Where required, further purification was achieved by crystallisation or preparative hplc. In some cases, an alternative work-up procedure was to partition the crude reaction mixture between water and an organic solvent. The organic extract was then dried (Na₂SO₄), evaporated
25 and purified as above.

Example 1

N-(4-Phenylpyridin-2-yl)isoquinolin-5-amine

Prepared from 2-chloro-4-phenylpyridine (Description 46) and isoquinolin-5-
30 amine according to the procedure of Description 69 to give a colourless solid (0.07 g, 17 %). *m/z* (ES⁺) 298 (M+H⁺).

Example 2**N-{4-[4-(Trifluoromethoxy)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethoxy)phenyl]pyridine (Description 44) and isoquinolin-5-amine according to the procedure of Description 69 to give a
5 colourless solid (0.085 g, 22 %). m/z (ES⁺) 382 (M+H⁺).

Example 3**N-{4-[3-(Trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[3-(trifluoromethyl)phenyl]pyridine (Description 45) and isoquinolin-5-amine according to the procedure of Description 69 to give a
10 colourless solid (0.105 g, 37 %). m/z (ES⁺) 366 (M+H⁺).

Example 4**N-{4-[4-(Trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and isoquinolin-5-amine according to the procedure of Description 69 to give a
15 lemon yellow solid (1.42 g, 54 %). m/z (ES⁺) 366 (M+H⁺).

Example 5**N-{5-[4-(Trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

To a mixture of 5-aminoisoquinoline (2.53 g, 17.5 mmol) and 2,5-dibromopyridine (3.62 g, 15.3 mmol) was added palladium acetate (0.17 g, 0.76 mmol) and rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.47 g, 0.76 mmol). The flask was flushed with nitrogen and p-xylene was added followed by sodium tert-butoxide
25 (2.2 g, 22.9 mmol). Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 130 °C for 12 hours under an atmosphere of nitrogen. The mixture was allowed to cool to room temperature and poured onto a mixture of chloroform/ water (200 ml/ 20 ml). The phases were separated and the aqueous phase was extracted twice with chloroform. The
30 combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flash chromatography (50% ethyl acetate- iso-hexane) followed by recrystallisation from ethanol gave
N-(5-bromopyridin-2-yl)isoquinolin-5-amine (3.4 g, 74 %). A portion (0.71 g, 2.37 mmol) was added to 4-(trifluoromethyl) phenylboronic acid (0.68 g,

3.59 mmol) in anhydrous dioxane (10 ml) and tetrakis(triphenylphosphino)-palladium (0) (0.14 g, 0.12 mmol) and saturated aqueous sodium carbonate solution (4 ml) were added. Nitrogen was bubbled through the mixture for 5 minutes and the reaction was then heated with stirring at 100 °C for 12 hours under an atmosphere of nitrogen. The mixture was allowed to cool to room temperature and poured into a mixture of ethyl acetate/ water (100 ml/ 30 ml). The phases were separated and the aqueous phase was extracted two times more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flash chromatography (50% ethyl acetate- iso-hexane) followed by recrystallisation from methanol/ water (1:1) yielded the title compound (0.22 g, 25 %). m/z (ES⁺) 366 (M+H⁺).

Example 6

5-({4-[4-(Trifluoromethyl)phenyl]pyridin-2-yl}oxy)isoquinoline
To a mixture of 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43, 0.22 g, 0.86 mmol) and 5-hydroxyisoquinoline (0.15 g, 1.0 mmol) in anhydrous *N,N*-dimethylacetamide (2.5 ml) was added sodium hydride (0.1 g, 2.5 mmol) in one portion under nitrogen. The mixture was heated with stirring at 150 °C for 15 hours under an atmosphere of nitrogen, allowed to cool to room temperature and poured into a mixture of chloroform/ water (30 ml/ 10 ml). The phases were separated and the aqueous phase was extracted two times more with chloroform. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel. Purification by flash chromatography (50% ethyl acetate- iso-hexane) followed by recrystallisation from ethanol/ water (1 : 1) gave the title compound (15 mg, 5 %) as an off-white solid. m/z (ES⁺) 367 (M+H⁺).

Example 7

N-{6-Methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine
Prepared from 2-chloro-6-methyl-4-[4-(trifluoromethyl)phenyl]pyridine (Description 51) and isoquinolin-5-amine according to the procedure of Description 69 to give a colourless solid (0.12 g, 23 %). m/z (ES⁺) 380 (M+H⁺).

Example 8**N-{6-Methoxy-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-6-methoxy-4-[4-(trifluoromethyl)phenyl]pyridine (Description 53) and isoquinolin-5-amine according to the procedure of Description 69 to give a colourless solid (0.15 g, 28 %). m/z (ES⁺) 396 (M+H⁺).

Example 9**N-{6-Chloro-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2,6-dichloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 48) and isoquinolin-5-amine according to the procedure of Description 69 to give a yellow solid (0.14 g, 29 %). m/z (ES⁺) 400 (M+H⁺).

Example 10**N-[6-Chloro-4-(pyridin-4-yl)pyridin-2-yl]isoquinolin-5-amine**

Prepared from 2,6-dichloro-4-(pyridin-4-yl)pyridine (Description 49) and isoquinolin-5-amine according to the procedure of Description 69 to give a colourless solid (0.08 g, 17 %). m/z (ES⁺) 333 (M+H⁺).

Example 11**3-Methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 3-methylisoquinolin-5-amine (Description 2) according to the procedure of Description 70 as a light brown solid (75 mg, 26%). m/z (ES⁺) 380 (M+H⁺).

Example 12**1-Methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 1-methylisoquinolin-5-amine (Description 4) according to the procedure of Description 70 as a yellow solid (63 mg, 21%). m/z (ES⁺) 380 (M+H⁺).

Example 13**6,8-Difluoro-3-methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43)
5 and 6,8-difluoro-3-methylisoquinolin-5-amine (Description 10) according to the
procedure of Description 70 as a white solid (69 mg, 19%). m/z (ES⁺) 416 (M+H⁺).

Example 14**3-Methyl-7-(trifluoromethyl)-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43)
and 3-methyl-7-(trifluoromethyl)isoquinolin-5-amine (Description 11) according
to the procedure of Description 70 as a white solid (190 mg, 50%). m/z (ES⁺) 448
(M + H⁺).

Example 15**8-Fluoro-3-methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43)
20 and 8-fluoro-3-methylisoquinolin-5-amine (Description 13) according to the
procedure of Description 70 as an off white solid (120 mg, 35%). m/z (ES⁺) 398
(M + H⁺).

Example 16**6-Fluoro-3-methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}isoquinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43)
and 6-fluoro-3-methylisoquinolin-5-amine (Description 16) according to the
procedure of Description 70 as a white solid (130 mg, 38%). m/z (ES⁺) 398 (M +
30 H⁺).

Example 17**N-{4-[4-(Trifluoromethyl)phenyl]pyridin-2-yl}quinolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and quinolin-5-amine according to the procedure of Description 69 to give a
5 colourless solid (0.095 g, 26 %). m/z (ES⁺) 366 (M+H⁺).

Example 18**3-Methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}cinnolin-5-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 3-methylcinnolin-5-amine according to the procedure of Description 69 to
10 give a green solid (0.195 g, 37 %). m/z (ES⁺) 380 (M+H⁺).

Example 19**1-Methyl-5-({4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino)quinolin-2(1H)-one**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 5-amino-1-methylquinolin-2(1H)-one (Description 20) in 1:1 stoichiometry according to the procedure of Description 70 as a light brown solid (20 mg, 18%).
15 m/z (ES⁺) 396 (M + H⁺).

Example 20**1-Methyl-5-({4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}amino)-3,4-dihydroquinolin-2(1H)-one**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 5-amino-1-methyl-3,4-dihydroquinolin-2(1H)-one (Description 19) in 1:1
20 stoichiometry according to the procedure of Description 70 as a light brown solid (22 mg, 19%). m/z (ES⁺) 398 (M + H⁺).

Example 21**1-Methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}-1H-indazol-4-amine**

Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 1-methyl-1H-indazol-4-amine (Description 22) according to the procedure of Description 69 to give a colourless solid (0.067 g, 28%). m/z (ES⁺) 369 (M+H⁺).
30

Example 22**N-{4-[4-(Trifluoromethyl)phenyl]pyridin-2-yl}-1*H*-indazol-4-amine**

Reaction of 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 1-[[2-(trimethylsilyl)ethoxy]methyl]-1*H*-indazol-4-amine (Description 25)

- 5 according to the procedure of Description 69 led to the SEM protected adduct (0.67 g, 52 %). This compound (0.60 g, 1.24 mmol) was dissolved in ethanol (20ml) and 6N HCl (5ml). was added. The reaction mixture was heated at reflux for 18 hours. The solvent was evaporated under reduced pressure and the residue partitioned between ethyl acetate and saturated sodium carbonate
- 10 solution. The ethyl acetate extracts were combined, washed with brine, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give an oil. The oil was purified by flash chromatography using hexane/ethyl acetate (3:1) (500ml) then hexane/ethyl acetate (1:1) as eluant to give an off-white solid which was triturated with hexane and collected by filtration (120mg, 27%).
- 15 *m/z* (ES⁺) 355 (M+H⁺).

Example 23**6-Fluoro-1-methyl-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}-1*H*-indazol-4-amine**

- 20 Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 6-fluoro-1-methyl-1*H*-indazol-4-amine (Description 32) according to the procedure of Description 70 as a white solid (95 mg, 29%). *m/z* (ES⁺) 387 (M + H⁺).

25 **Example 24**

1-Methyl-6-(trifluoromethyl)-N-{4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}-1*H*-indazol-4-amine

- Prepared from 2-chloro-4-[4-(trifluoromethyl)phenyl]pyridine (Description 43) and 1-methyl-6-(trifluoromethyl)-1*H*-indazol-4-amine (Description 33) according
- 30 to the procedure of Description 70 as a white solid (104 mg, 28%). *m/z* (ES⁺) 437 (M + H⁺).

Example 25**N-[5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl]isoquinolin-5-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and isoquinolin-5-amine according to the procedure of Description 69 to give an orange solid (0.44 g, 42 %). m/z (ES⁺) 367 (M+H⁺).

Example 26**N-(5-[3-(Cyano)phenyl]pyridazin-3-yl)isoquinolin-5-amine**

Prepared from 3-chloro-5-(3-cyanophenyl)pyridazine (Description 58) and isoquinolin-5-amine according to the procedure of Description 69 to give a light brown solid (0.11 g, 30 %). m/z (ES⁺) 324 (M+H⁺).

Example 27**N-[5-(4-Methoxyphenyl)pyridazin-3-yl]isoquinolin-5-amine**

Prepared from 3-chloro-5-(4-methoxyphenyl)pyridazine (Description 62) and isoquinolin-5-amine according to the procedure of Description 70 as an off-white solid (37 mg, 11%). m/z (ES⁺) 329 (M+H⁺).

Example 28**N-[5-(4-tert-Butylphenyl)pyridazin-3-yl]isoquinolin-5-amine**

Prepared from 5-(4-tert-butylphenyl)-3-chloropyridazine (Description 56) and isoquinolin-5-amine according to the procedure of Description 70 as an off-white solid (233 mg, 34%). m/z (ES⁺) 355 (M+H⁺).

Example 29**N-[5-[2-Fluoro-4-(trifluoromethyl)phenyl]pyridazin-3-yl]isoquinolin-5-amine**

Prepared from 3-chloro-5-[2-fluoro-4-(trifluoromethyl)phenyl]pyridazine (Description 64) and isoquinolin-5-amine according to the procedure of Description 70 as an off-white solid (120 mg, 21%). m/z (ES⁺) 385 (M+H⁺).

Example 30**N-{6-Chloro-5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine**

Prepared from 3,6-dichloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 59) and isoquinolin-5-amine according to the procedure of Description 69 to give a brown solid (0.66 g, 23 %). m/z (ES⁺) 401 (M+H⁺).

Example 31**N-[5-(3-Methylpyridin-2-yl)pyridazin-3-yl]isoquinolin-5-amine**

Prepared from 3-chloro-5-(3-methylpyridin-2-yl)pyridazine (Description 60) and isoquinolin-5-amine according to the procedure of Description 70 as a light green solid (88mg, 32%). m/z (ES⁺) 314 (M+H⁺).

Example 32**N-{4,5-bis[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine**

To a mixture of N-{6-chloro-5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine (Example 30, 0.08 g, 0.2 mmol) and 4-(trifluoromethyl)phenylboronic acid (0.057 g, 0.3 mmol) in anhydrous dioxane (2 ml) was added (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.007 g, 0.009 mmol) and saturated aqueous sodium carbonate solution (0.3 ml).

The mixture was irradiated in a microwave reactor at 170 °C for 10 minutes, allowed to cool to room temperature and poured onto a mixture of chloroform/water (30 ml/ 10 ml). The phases were separated and the aqueous phase was extracted two times more with chloroform. The combined organic layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel.

Purification by flash column chromatography (ethyl acetate) yielded the title compound (35 mg, 34 %) as a yellow solid. m/z (ES⁺) 511 (M+H⁺).

Example 33**3-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 3-methylisoquinolin-5-amine (Description 2) according to the procedure of Description 70 as a yellow solid (6 mg, 2%). m/z (ES⁺) 381 (M+H⁺).

Example 34**1-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 1-methylisoquinolin-5-amine (Description 4) according to the procedure of Description 70 as a light brown solid (20 mg, 2%). m/z (ES⁺) 381 (M+H⁺).

Example 35**N-{5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}-5,6,7,8-tetrahydroisoquinolin-5-amine**

To a solution of 3,6-dichloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 59, 786 mg, 2.68 mmol) in anhydrous dimethylacetamide (2 ml) was added 5,6,7,8-tetrahydroisoquinolin-5-amine (Description 5, 397 mg, 2.68 mmol). The reaction mixture was heated at 100°C for 24 hours then cooled and partitioned between ethyl acetate (15 ml) and water (15 ml). The aqueous layer was extracted with more ethyl acetate (15 ml) and the combined organic phases washed with water (2 x 20 ml), then dried (MgSO₄), filtered and evaporated to give a brown oil. Purification by flash column chromatography on silica using 6% methanol in dichloromethane as the eluant gave a brown oil (450 mg, 42%). This oil (450 mg, 1.1 mmol) was dissolved in methanol (10 ml) and 10% palladium on carbon (100 mg), and ammonium formate (700 mg, 11 mmol, 10 eq) were added and the reaction heated at 50°C for 90 minutes. The reaction was cooled, then filtered and the solvent evaporated. The resulting solid was extracted into ethyl acetate (2 x 30 ml) and washed with water (2 x 30 ml), the organic layer was then dried over MgSO₄, filtered and evaporated. The resulting brown oil was purified by column chromatography on silica eluting with 3% methanol in dichloromethane with 0.5% ammonia to give the title compound as a white solid (31mg, 8%). m/z (ES⁺) 371 (M + H⁺).

Example 36**6,8-Difluoro-3-methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 6,8-difluoro-3-methylisoquinolin-5-amine (Description 10) according to the

procedure of Description 70 as an off white solid (34 mg, 9%). m/z (ES^+) 417 ($M + H^+$).

Example 37

5 3-Methyl-7-(trifluoromethyl)-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 3-methyl-7-trifluoromethylisoquinolin-5-amine (Description 11) according to the procedure of Description 70 as an off white solid (63 mg, 16%). m/z (ES^+) 449
10 ($M + H^+$).

Example 38

8-Fluoro-3-methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine

15 Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 8-fluoro-3-methylisoquinolin-5-amine (Description 13) according to the procedure of Description 70 as an off white solid (26 mg, 7%). m/z (ES^+) 399 ($M + H^+$).

Example 39

20 6-Fluoro-3-methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}isoquinolin-5-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 6-fluoro-3-methylisoquinolin-5-amine (Description 16) according to the
25 procedure of Description 70 as an off white solid (56 mg, 16%). m/z (ES^+) 399 ($M + H^+$).

Example 40

3-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}cinnolin-5-amine

30 Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 3-methylcinnolin-5-amine according to the procedure of Description 70 as a yellow solid (75 mg, 23%). m/z (ES^+) 382 ($M + H^+$).

Example 41**1-Methyl-5-({5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}amino)quinolin-2(1H)-one**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 5-amino-1-methylquinolin-2(1H)-one (Description 20) in 1:1 stoichiometry according to the procedure of Description 70 as a light brown solid (35 mg, 36%). m/z (ES⁺) 397 (M + H⁺).

Example 42**1-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}-1H-indazol-4-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 1-methyl-1H-indazol-4-amine (Description 22) according to the procedure of Description 69 as a yellow solid (16 mg, 3%). m/z (ES⁺) 370 (M + H⁺).

Example 43**2-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}-2H-indazol-4-amine**

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 2-methyl-2H-indazol-4-amine (Description 23) according to the procedure of Description 70 as an off-white solid (10 mg, 11%). m/z (ES⁺) 370 (M + H⁺).

Example 44**N-{5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}-1H-indazol-4-amine**

Reaction of 3,6-dichloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 59) and 1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazol-4-amine (Description 25) according to the procedure of Description 70 gave the coupled product (595 mg, 1.1 mmol) which was dissolved in methanol (5 ml). 10% Palladium on carbon (100 mg) and ammonium formate (693 mg, 11 mmol, 10 eq) were added and the reaction heated at 50°C for 3 hours. The reaction was cooled, then filtered and the solvent evaporated. The resulting solid was partitioned between ethyl acetate (30 ml) and water (30 ml) and the aqueous phase extracted with ethyl acetate (30 ml). The combined organic phases were washed with water (2 x 30 ml), then dried over MgSO₄ and evaporated to give the dechlorinated compound (568 mg, quantitative). This compound (475 mg, 0.98 mmol) was dissolved in ethanol (20 ml), hydrochloric acid (5N, 6 ml) was added and the

solution heated at 80°C for 30 minutes. The reaction was cooled, the solvent evaporated and the residue partitioned between ethyl acetate (50 ml) and water (30 ml). The aqueous phase was extracted with ethyl acetate (30 ml) and the combined organic phases were washed with saturated aqueous sodium carbonate (50ml), brine (50 ml) and water (50 ml), then dried over MgSO₄ and evaporated. The yellow oil was purified by flash column chromatography on silica eluting with 75% ethyl acetate in dichloromethane, and the resulting solid triturated with diethyl ether and hexane to give the title compound as a yellow solid (148 mg, 43%). m/z (ES⁺) 356 (M + H⁺).

Example 45

6-Fluoro-1-methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}-1H-indazol-4-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 6-fluoro-1-methyl-1H-indazol-4-amine (Description 32) according to the procedure of Description 70 as a white solid (80 mg, 24%). m/z (ES⁺) 388 (M + H⁺).

Example 46

1-Methyl-6-(trifluoromethyl)-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}-1H-indazol-4-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 1-methyl-6-(trifluoromethyl)-1H-indazol-4-amine (Description 33) according to the procedure of Description 70 as a white solid (24 mg, 6%). m/z (ES⁺) 438 (M + H⁺).

Example 47

N-{5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}imidazo[1,5- α]pyridin-8-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and imidazo[1,5- α]pyridin-8-amine (Description 39) according to the procedure of Description 70 as an off white solid (80 mg, 10%). m/z (ES⁺) 356 (M + H⁺).

Example 48

N-{5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}imidazo[1,2-a]pyridin-5-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and imidazo[1,2-a]pyridin-5-amine (*Medicinal Chemistry Research*, 1997, 7(8), 436-464) according to the procedure of Description 70 as an off white solid (120 mg, 15%). m/z (ES⁺) 356 (M + H⁺).

Example 49

N-{5-[4-(Trifluoromethyl)phenyl]pyridazin-3-yl}[1,2,3]triazolo[1,5-a]pyridin-4-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and [1,2,3]triazolo[1,5-a]pyridin-4-amine (Description 42) according to the procedure of Description 70 as an orange solid (22 mg, 4%). m/z (ES⁺) 329 (M + H⁺).

Example 50

2-Methyl-N-{5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl}-1,3-benzothiazol-6-amine

Prepared from 3-chloro-5-[4-(trifluoromethyl)phenyl]pyridazine (Description 54) and 6-amino-2-methylbenzothiazole according to the procedure of Description 70 as a yellow solid (120 mg, 25%). m/z (ES⁺) 387 (M + H⁺).

Example 51

N-[6-(4-Fluorophenyl)pyridazin-4-yl]isoquinolin-5-amine

Prepared from 5-chloro-3-(4-fluorophenyl)pyridazine (Description 65) and isoquinolin-5-amine according to the procedure of Description 69 as a colourless solid (35 mg, 31%). m/z (ES⁺) 317 (M+H⁺).

Example 52

N-{6-[4-(Trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and isoquinolin-5-amine according to the procedure of Description 69 as an off white solid (50mg, 7%). m/z (ES⁺) 367 (M + H⁺).

Example 53

3-Methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 3-methylisoquinolin-5-amine (Description 2) according to the procedure of Description 70 as a pink solid (16 mg, 5.4%). m/z (ES⁺) 381 (M + H⁺).

Example 54

1-Methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 1-methylisoquinolin-5-amine (Description 4) according to the procedure of Description 70 as an off-white solid (13 mg, 4.4%). m/z (ES⁺) 381 (M + H⁺).

Example 55

N-{6-[4-(Trifluoromethyl)phenyl]pyrimidin-4-yl}-5,6,7,8-tetrahydroisoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 5,6,7,8-tetrahydroisoquinolin-5-amine (Description 5) according to the procedure of Description 70 as an off-white solid (6 mg, 1%). m/z (ES⁺) 371 (M + H⁺).

Example 56

6,8-Difluoro-3-methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 6,8-difluoro-3-methylisoquinolin-5-amine (Description 10) according to the procedure of Description 70 as an off white solid (130 mg, 37%). m/z (ES⁺) 417 (M + H⁺).

Example 57

3-Methyl-7-(trifluoromethyl)-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 3-methyl-7-(trifluoromethyl)isoquinolin-5-amine (Description 11) according

to the procedure of Description 70 as an off white solid (154 mg, 40%). m/z (ES^+) 449 ($M + H^+$).

Example 58

5 8-Fluoro-3-methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 8-fluoro-3-methylisoquinolin-5-amine (Description 13) according to the procedure of Description 70 as an off white solid (83 mg, 24%). m/z (ES^+) 399 ($M + H^+$).

Example 59

15 6-Fluoro-3-methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 6-fluoro-3-methylisoquinolin-5-amine (Description 16) according to the procedure of Description 70 as an off white solid (65 mg, 19%). m/z (ES^+) 399 ($M + H^+$).

20 Example 60

3-Methyl-N-{2-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}isoquinolin-5-amine

Prepared from 4-chloro-2-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 68) and 3-methylisoquinolin-5-amine (Description 2) according to the procedure of Description 70 as an off white solid (35 mg, 4%). m/z (ES^+) 395 ($M+H^+$).

Example 61

30 3-Methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}cinnolin-5-amine

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 3-methylcinnolin-5-amine according to the procedure of Description 70 as a yellow solid (36 mg, 11%). m/z (ES^+) 382 ($M + H^+$).

Example 62**1-Methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}-1H-indazol-4-amine**

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 1-methyl-1H-indazol-4-amine (Description 22) according to the procedure of Description 69 as a yellow solid (17 mg, 3%). m/z (ES⁺) 370 (M + H⁺).

Example 63**N-{6-[4-(Trifluoromethyl)phenyl]pyrimidin-4-yl}-1H-indazol-4-amine**

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazol-4-amine (Description 25) according to the procedure of Example 44 as a yellow solid (20 mg, 10%). m/z (ES⁺) 356 (M + H⁺).

Example 64**6-Fluoro-1-methyl-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}-1H-indazol-4-amine**

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 6-fluoro-1-methyl-1H-indazol-4-amine (Description 32) according to the procedure of Description 70 as an off white solid (17 mg, 5%). m/z (ES⁺) 388 (M + H⁺).

Example 65**1-Methyl-6-(trifluoromethyl)-N-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}-1H-indazol-4-amine**

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and 1-methyl-6-(trifluoromethyl)-1H-indazol-4-amine (Description 33) according to the procedure of Description 70 as a white solid (53 mg, 14%). m/z (ES⁺) 438 (M + H⁺).

Example 66**N-{6-[4-(Trifluoromethyl)phenyl]pyrimidin-4-yl}[1,2,3]triazolo[1,5-a]pyridin-4-amine**

Prepared from 4-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidine (Description 66) and [1,2,3]triazolo[1,5-a]pyridin-4-amine (Description 42) according to the

procedure of Description 70 as a yellow solid (15 mg, 3%). m/z (ES⁺) 329 (M + H⁺).

The above exemplified compounds of the present invention have been tested in
5 the following assay and generally possess an IC₅₀ < 1 μ M and, in the majority of cases, < 200 nM.

Biological Methodology

Determination of *in vitro* activity

10 CHO cells, stably expressing recombinant human VR1 receptors and plated into black-sided 384-well plates, were washed twice with assay buffer (Hepes-buffered saline) and then incubated with 1 μ M Fluo-3-AM for 60 minutes in darkness. Cells were washed twice more to remove excess dye, before being placed, along with plates containing capsaicin and test compounds in a Molecular Devices
15 FLIPR. The FLIPR simultaneously performed automated pharmacological additions and recorded fluorescence emission from Fluo-3. In all experiments, basal fluorescence was recorded, before addition of test compounds and subsequent addition of a previously determined concentration of capsaicin that evoked 80% of the maximum response. Inhibition of capsaicin evoked increases
20 in intracellular [Ca²⁺] were expressed relative to wells on the same plate to which capsaicin was added in the absence of test compounds. Increases in intracellular [Ca²⁺] occurring after addition of test compound alone, prior to addition of capsaicin, allow determination of intrinsic agonist or partial agonist activity, if present.

25

Determination of *in vivo* efficacy in a capsaicin paw flinch model

(Method adapted from Taniguchi *et al*, 1997, *Br J Pharmacol*. 122(5):809-12)

To determine *in vivo* functional occupancy of VR1 receptors, compounds are administered orally to male Sprague Dawley rats typically 1 hour prior to
30 receiving an intraplantar injection of capsaicin (2 μ g dissolved in ethanol) and the number of flinches of the injected paw is recorded for 5 minutes immediately thereafter. Statistical analysis is performed using one-way ANOVA followed by Dunnett's test; p values <0.05 compared to capsaicin/vehicle-treated rats are considered significant.

Determination of *in vivo* efficacy in a model of inflammatory pain

(Method adapted from Hargreaves *et al*, 1988 *Pain*, 32(1):77-88).

Antinociceptive activity is determined using a rat carrageenan-induced thermal
5 hyperalgesia assay. Inflammatory hyperalgesia is induced by intraplantar
injection of carrageenan (lambda-carrageenan 0.1 ml of 1% solution made up in
saline) into one hind paw. Compounds are given orally typically 2 hours after
carrageenan and paw withdrawal latencies determined 1 hour later. Paw
withdrawal latencies to application of noxious thermal stimuli to plantar surface
10 of the hind paw are measured using the Hargreaves apparatus. Thermal
hyperalgesia is defined as the difference in paw withdrawal latencies for
saline/vehicle- and carrageenan/vehicle-treated rats. Paw withdrawal latencies
for drug treated rats are expressed as a percentage of this response. Statistical
analysis is performed using one-way ANOVA followed by Dunnett's test; p values
15 <0.05 compared to carrageenan/vehicle-treated rats are considered significant.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.